



(11) **EP 2 173 717 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims EN 1

(48) Corrigendum issued on:
26.06.2013 Bulletin 2013/26

(45) Date of publication and mention
of the grant of the patent:
27.03.2013 Bulletin 2013/13

(21) Application number: **08782284.7**

(22) Date of filing: **24.07.2008**

(51) Int Cl.:
C07D 213/81 ^(2006.01) **C07D 231/14** ^(2006.01)
C07D 233/90 ^(2006.01) **C07D 241/24** ^(2006.01)
C07D 249/10 ^(2006.01) **C07D 277/56** ^(2006.01)
C07D 277/68 ^(2006.01) **C07D 471/04** ^(2006.01)
C07D 513/04 ^(2006.01) **C07C 237/22** ^(2006.01)
A61K 31/426 ^(2006.01) **A61K 31/4196** ^(2006.01)
A61K 31/4164 ^(2006.01) **A61P 3/00** ^(2006.01)

(86) International application number:
PCT/US2008/070962

(87) International publication number:
WO 2009/018065 (05.02.2009 Gazette 2009/06)

(54) **NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME**
NEUARTIGE GLUCOKINASE-AKTIVATOREN UND VERFAHREN ZU IHRER VERWENDUNG
NOUVEAUX ACTIVATEURS DE GLUCOKINASE ET PROCÉDÉS POUR LES UTILISER

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **27.07.2007 US 952273 P**

(43) Date of publication of application:
14.04.2010 Bulletin 2010/15

(73) Proprietor: **Bristol-Myers Squibb Company**
Princeton, NJ 08543-4000 (US)

(72) Inventors:
• **SHI, Yan**
Pennington, NJ 08534 (US)
• **CHENG, Peter, T., W.**
Pennington, NJ 08534 (US)
• **WANG, Ying**
Pennington, NJ 08534 (US)
• **RYONO, Denis, E.**
Minneapolis, MN 55401 (US)

(74) Representative: **Reitstötter - Kinzebach**
Patentanwälte
Sternwartstrasse 4
81679 München (DE)

(56) References cited:
EP-A- 1 690 863 WO-A-00/69849
WO-A-01/05769 WO-A-03/035621
WO-A-03/037332 WO-A-03/106427
WO-A-2004/099155 WO-A-2005/032493
WO-A-2006/112549 WO-A-2007/061923
JP-A- 2003 300 875 US-A- 4 261 730

- **MCKERRECHER D ET AL: "Discovery, synthesis and biological evaluation of novel glucokinase activators" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 8, 15 April 2005 (2005-04-15), pages 2103-2106, XP004829182 ISSN: 0960-894X**
- **HADDEN ET AL: "Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 18, 2007, pages 5063-5067, XP022206823 available online 13 July 2007 ISSN: 0960-894X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 173 717 B9

Description

FIELD OF THE INVENTION

[0001] The present invention relates to novel amide compounds which are activators of the enzyme glucokinase and thus are useful in treating diabetes, and to using these compounds in a method for treating diabetes, especially Type II diabetes.

BACKGROUND OF THE INVENTION

[0002] The enzyme glucokinase (GK), which is mainly found in pancreatic β -cells and liver parenchymal cells, catalyzes the conversion of glucose to glucose-6-phosphate, which is the first step in the metabolism of glucose. Glucokinase is also a rate-controlling enzyme for glucose metabolism in pancreatic β -cells and liver parenchymal cells, which play an important role in whole-body glucose homeostasis.


[0003] Liag, Y. et al., (Biochem. J., 309:167-173 (1995)) report the finding that Type II (maturity-onset) diabetes of the young (MODY-2) is caused by loss of function mutations in the glucokinase gene, which suggests that glucokinase also functions as a glucose sensor in humans. Thus, compounds that activate glucokinase and thus increase the sensitivity of the glucokinase sensor system and thereby cause increase in insulin secretion will be useful in the treatment of hyperglycemia and Type II diabetes. Compounds that may be used to activate glucokinase are disclosed in WO 2007/061923 A.

[0004] Glucokinase activators have been demonstrated to be effective in enhancing: 1) the effect of glucose on insulin release from isolated rat and human pancreatic islets, and 2) the glucose induction of pancreatic islet glucokinase in isolated cultured rat islets (e.g., Matschinsky, F.M. et al., Diabetes, 55:1 (2006), and Matschinsky, F.M. et al., eds., Glucokinase and Glycemic Disease, from Basics to Novel Therapeutics, Karger, publ., Ch. 6, pp. 360-378 (2004)). In diabetic animal model studies, glucokinase activators have been demonstrated to stimulate insulin release, enhance glycogen synthesis and reduce hepatic glucose production in pancreatic clamp studies. Importantly, glucokinase activators have been demonstrated to dose-dependently lower blood glucose levels in different standard animal models of type 2 diabetes, such as the *ob/ob* mouse, *db/db* mouse and Zucker *fafa* rat in acute single-dose studies and also effectively improved the glucose excursion in both normal C57/BL6J and *ob/ob* mice in oral glucose tolerance tests (e.g., in Matschinsky, F.M. et al., eds., Glucokinase and Glycemic Disease, from Basics to Novel Therapeutics, Karger, publ., Ch. 6, pp. 360-378 (2004) as well as Fyfe, M.C. et al., Diabetologia, 50:1277 (2007)).

[0005] Glucokinase activators have also demonstrated antidiabetic efficacy in chronic animal models of type II diabetes. For instance, in a 9-day study in *ob/ob* mice, a glucokinase activator improved the overall glucose profile while showing comparable antihyperglycemic effects in oral glucose tolerance tests at the beginning and end of the study (Fyfe, M.C. et al., Diabetologia, 50:1277 (2007)). In another instance, in a chronic 40-week study, a glucokinase activator prevented the development of hyperglycemia in diet-induced obese mice which were glucose intolerant. The diet-induced obese mice treated with a glucokinase activator showed marked improvement in the glucose excursion in an oral glucose tolerance test at the end of the study relative to the control group (Matschinsky, F.M. et al., eds., Glucokinase and Glycemic Disease, from Basics to Novel Therapeutics, Karger, publ., Ch. 6, pp. 360-378 (2004)).

SUMMARY OF THE INVENTION

[0006] In accordance with one aspect of the invention, compounds are provided having the structure I



I

or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof;

where Q is R^1 optionally substituted with one or two additional substituents independently chosen from R^4 and R^5 that may be the same or different;

R^1 is a monocyclic or bicyclic heteroaryl ring, containing a nitrogen atom adjacent to the carbonyl linked ring carbon and

possessing one additional nitrogen atom, and when substituents are attached to a N atom of the ring, a quarternary nitrogen center is not formed;

R⁴ and R⁵ are the same or different and are independently selected from alkyl, arylalkyl, alkoxycarbonyl, or carboxyl; R⁶ is H;

R⁷ and R⁸ (regardless of which group each is a part of) are the same or different and are independently selected from H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R⁷ and R⁸ are cyclized together to form a 3- to 7-membered heterocycle;

R⁹ (regardless of which group it is a part of) is independently selected from H, alkyl, aryl, or arylalkyl;

R¹⁰ (regardless of which group it is a part of) is independently selected from alkyl, aryl, heteroaryl, aralkyl, or heteroarylalkyl;

R² is Y-Z-;


Z is O or a bond;

Y is C₁₋₆alkyl-, aryl-, heterocyclyl-, or heteroaryl-;

wherein each Y is independently optionally substituted by up to 3 R¹² groups;

each R¹² is independently selected from F, Cl, Br, I, -CH₃-aF_a, CN, NO₂ NH₂, C₁₋₆alkyl, OC₁₋₆alkyl, -COOH, OH, aryloxy, heteroaryloxy, heterocyclyloxy, -S-R¹⁰, -S(O)-R¹⁰, -SO₂R⁹, -SO₂NR⁷R⁸, -NR⁷R⁸, -CO₂R⁹, -C(O)N⁷R⁸, N-linked amide (-NR⁷C(O)R⁸), N-linked sulfonamide (-NR⁹SO₂R¹⁰), N-linked carbamate (-NR⁸CO₂R¹⁰), O-linked carbamate (-OCONR⁷R⁸), N-linked urea (-NR⁹C(O)NR⁷R⁸), -(CH₂)_p-PO(OR⁷)(OR⁸), -(CH₂)_p-PO(OR⁷)R⁸, -(CH₂)_p-O-PO(OR⁷)R⁸, -(CH₂)_p-O-PO-(R⁷)R⁸, -(CH₂)_p-P(O)R⁷R⁸, aryl, heteroaryl, or heterocyclyl;

R³ is



each a is an integer independently selected from 1, 2, 3; and

p is an integer independently selected from 0, 1 or 2

wherein "cycloalkyl" includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings.


[0007] By the term "independently selected from" refers to the use of the same variable or substituent designation more than once in the same molecule and each such use is independent of each other, for example,

- (1) R⁷ and/or R⁸ used more than once in the same molecule;
- or (2) R⁹ and/or R¹⁰ used more than once in the same molecule.

[0008] Preferably, in the compounds of formula I,

Q is an R¹ ring which is a 5- or 6-membered monocyclic heteroaryl ring or Q is an R¹ ring which is an 8-, 9- or 10-membered bicyclic heteroaryl.

[0009] Examples of preferred Q heteroaryl rings include, but are not limited to





[0010] R² is preferably Y-Z- where

Z is preferably O or a bond; and


Y is C₁₋₆alkyl-, aryl-, heterocyclyl-, or heteroaryl-.

[0011] Examples of preferred R² groups include, but are not limited to,




[0012] More preferred are compounds of formula I where


R^1 is



and R^2 is



[0013] An example of a preferred compound in accordance with the present invention, includes, but is not limited to the following:



[0014] The compounds of the present invention activate or enhance the activity of the enzyme glucokinase. Consequently, the compounds of the present invention may be used in the treatment of multiple diseases or disorders associated with a deficit of glucokinase, such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, and other maladies. Examples of diseases or disorders associated with deficit in activity of

the enzyme glucokinase that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, and glaucoma.

[0015] The present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds, and for compounds for use in methods of therapy. In particular, the present invention provides a pharmaceutical composition containing a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier.

[0016] Further, in accordance with the present invention, compounds for use in a method are provided for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with deficit in the activity of the enzyme glucokinase, such as defined above and hereinafter, wherein a therapeutically effective amount of a compound of formula I is administered to a mammalian, i.e., human, patient in need of treatment.

[0017] The compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agent(s).

[0018] Further, the present invention provides compounds for use in a method for preventing, inhibiting, or treating the diseases as defined above and hereinafter, wherein a therapeutically effective amount of a combination of a compound of formula I and another compound of formula I and/or at least one other type of therapeutic agent, is administered to a mammalian, i.e., human, patient in need of treatment.

[0019] In another embodiment, compounds of the present invention are selected from the compounds exemplified in the examples.

[0020] In another embodiment, the present invention relates to pharmaceutical compositions which include of a therapeutically effective amount of a compound of the present invention, alone or, optionally, in combination with a pharmaceutically acceptable carrier and/or one or more other agent(s).

[0021] In another embodiment, the present invention relates to compounds for use in methods of enhancing the activity of the enzyme glucokinase which includes the step of administering to a mammalian patient, for example, a human patient, in need thereof a therapeutically effective amount of a compound of the present invention, alone, or optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0022] In another embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with deficit in the activity of the enzyme glucokinase which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0023] Examples of diseases or disorders associated with the deficit in activity of the enzyme glucokinase that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, are those diseases or disorders set out above.

[0024] In another embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0025] In still another embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of diabetes, which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0026] In yet still another embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of hyperglycemia which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0027] In another embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of obesity which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at

least one other type of therapeutic agent.

[0028] In one embodiment, the present invention relates to compounds for use in a method for preventing, inhibiting, or treating the progression or onset of dyslipidemia, which includes the step of administering to a mammalian patient, for example, a human patient, in need of prevention, inhibition, or treatment a therapeutically effective amount of a compound of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms, and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.


[0030] The term "substituted," as used herein, means that any one or more hydrogens on the designated atom or ring is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

[0031] When any variable (e.g., R⁷ and/or R⁸) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R⁷ and/or R⁸, then said group may optionally be substituted with up to two R⁷ and/or R⁸ groups and R⁷ and/or R⁸ at each occurrence is selected independently from the definition of R^a. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0032] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0033] Unless otherwise indicated, the term "lower alkyl," "alkyl," or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like.

[0034] Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl), and tricyclic alkyl, containing a total of 3 to 20 carbons forming the ring, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,



any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl.

[0035] Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio, and/or any of the alkyl substituents set out herein.


[0036] Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butylnyl, 2-butylnyl, 4-pentylnyl, 3-pentylnyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonylnyl, 4-decynyl, 3-undecynyl, 4-dodecynyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein.

[0037] Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".

[0038] Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

[0039] The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF_3 , with chlorine or fluorine being preferred.

[0040] Unless otherwise indicated, the term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl, biphenyl or naphthyl, including 1-naphthyl and 2-naphthyl) and may optionally include 1 to 3 additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl, or cycloheteroalkyl rings) for example



[0041] Unless otherwise indicated, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to an oxygen atom

[0042] Unless otherwise indicated, the term "amino" as employed herein alone or as part of another group refers to amino that may be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the R_3 groups or substituents for R_3 as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl, or hydroxy.

[0043] Unless otherwise indicated, the term "lower alkylthio", "alkylthio", "arylthio", or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl, or aryl groups linked to a sulfur atom.


[0044] Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl, or arylalkyl groups linked to a nitrogen atom.

[0045] The term "acyl" alone or as part of another group refers to a carbonyl group linked to an organic radical, more particularly, the group $C(=O)R_e$, as well as the bivalent groups $-C(=O)-$ or $-C(=O)R_e-$, which are linked to organic radicals. The group R_e can be selected from alkyl, alkenyl, alkynyl, aminoalkyl, substituted alkyl, substituted alkenyl, or substituted alkynyl, as defined herein, or when appropriate, the corresponding bivalent group, e.g., alkylene, alkenylene, and the like.

[0046] The term "heterocyclo" or "heterocyclic" or "heterocyclyl" or "cycloheteroalkyl" refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N) (also referred to as cycloheteroalkyl or heterocycloalkyl). Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The fused rings completing bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The heterocyclo group may be attached at any available nitrogen or carbon atom. The heterocyclo ring may contain zero, one, two, or three substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, nitro, cyano, oxo ($=O$), OR_a , SR_a , $(=S)$, $-NR_aR_b$, $-N(alkyl)_3^+$, $-NR_aSO_2$, $-NR_aSO_2R_c$, $-SO_2R_c$, $-SO_2NR_aR_b$, $-SO_2NR_a(=O)R_b$, SO_3H , $-PO(OH)_2$, $-C(=O)R_a$, $-CO_2R_a$, $-C(=O)NR_aR_b$, $-C(=O)(C_{1-4}alkylene)NR_aR_b$, $-C(=O)NR_a(SO_2)R_b$, $-CO_2(C_{1-4}alkylene)NR_aR_b$, $-NR_aC(=O)R_b$, $-NR_aCO_2R_b$, $-NR_a(C_{1-4}alkylene)CO_2R_b$, $=N-OH$, $=N-O-alkyl$, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a , R_b , and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above. When a heterocyclo is substituted with a further ring, said ring in turn is optionally substituted with one to two of $(C_{1-4})alkyl$, $(C_{2-4})alkenyl$, halogen, hydroxy, cyano, nitro, CF_3 , $O(C_{1-4}alkyl)$, OCF_3 , $C(=O)H$, $C(=O)(C_{1-4}alkyl)$, CO_2H , $CO_2(C_{1-4}alkyl)$, $NHCO_2(C_{1-4}alkyl)$, $-S(C_{1-4}alkyl)$, $-NH_2$, $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$, $N(C_{1-4}alkyl)_3^+$, $SO_2(C_{1-4}alkyl)$, $C(=O)(C_{1-4}alkylene)NH_2$, $C(=O)(C_{1-4}alkylene)NH(alkyl)$, and/or $C(=O)(C_{1-4}alkylene)N(C_{1-4}alkyl)_2$.

[0047] Exemplary monocyclic groups include azetidiny, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, and tetrahydro-1,1-dioxothienyl, and the like. Exemplary bicyclic heterocyclo groups include quinuclidinyl.

[0048] Preferred heterocyclo groups in compounds of formula (I) include



and



which optionally may be substituted.


[0049] The term "heteroaryl" alone or as part of another group refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated, and may include aryl, cycloalkyl, heteroaryl or cycloheteroaryl. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may contain zero, one, two or three substituents which may be any of the substituents set out for alkyl and can be selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, nitro, cyano, OR_a , SR_a , $(=\text{S})$, $-\text{NR}_a\text{R}_b$, $-\text{N}(\text{alkyl})_3^+$, $-\text{NR}_a\text{SO}_2$, $-\text{NR}_a\text{SO}_2\text{R}_c$, $-\text{SO}_2\text{R}_c$, $-\text{SO}_2\text{NR}_a\text{R}_b$, $-\text{SO}_2\text{NR}_a\text{C}(=\text{O})\text{R}_b$, SO_3H , $-\text{PO}(\text{OH})_2$, $-\text{C}(=\text{O})\text{R}_a$, $-\text{CO}_2\text{R}_a$, $-\text{C}(=\text{O})\text{NR}_a\text{R}_b$, $-\text{C}(=\text{O})(\text{C}_{1-4}\text{alkylene})\text{NR}_a\text{R}_b$, $-\text{C}(=\text{O})\text{NR}_a(\text{SO}_2)\text{R}_b$, $-\text{CO}_2(\text{C}_{1-4}\text{alkylene})\text{NR}_a\text{R}_b$, $-\text{NR}_a\text{C}(=\text{O})\text{R}_b$, $-\text{NR}_a\text{CO}_2\text{R}_b$, $-\text{NR}_a(\text{C}_{1-4}\text{alkylene})\text{CO}_2\text{R}_b$, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a , R_b and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above. When a heteroaryl is substituted with a further ring, said ring in turn is optionally substituted with one to two of (C_{1-4}) alkyl, (C_{2-4}) alkenyl, halogen, hydroxy, cyano, nitro, CF_3 , $\text{O}(\text{C}_{1-4}\text{alkyl})$, OCF_3 , $\text{C}(=\text{O})\text{H}$, $\text{C}(=\text{O})(\text{C}_{1-4}\text{alkyl})$, CO_2H , $\text{CO}_2(\text{C}_{1-4}\text{alkyl})$, $\text{NHCO}_2(\text{C}_{1-4}\text{alkyl})$, $-\text{S}(\text{C}_{1-4}\text{alkyl})$, $-\text{NH}_2$, $\text{NH}(\text{C}_{1-4}\text{alkyl})$, $\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $\text{N}(\text{C}_{1-4}\text{alkyl})_3^+$, $\text{SO}_2(\text{C}_{1-4}\text{alkyl})$, $\text{C}(=\text{O})(\text{C}_{1-4}\text{alkylene})\text{NH}_2$, $\text{C}(=\text{O})(\text{C}_{1-4}\text{alkylene})\text{NH}(\text{alkyl})$, and/or $\text{C}(=\text{O})(\text{C}_{1-4}\text{alkylene})\text{N}(\text{C}_{1-4}\text{alkyl})_2$.


[0050] Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolynyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.

[0051] Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolynyl, tetrahydroisoquinolynyl, isoquinolynyl, benzimidazolyl, benzopyranyl, indolizynyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolynyl, quinoxalynyl, indazolyl, pyrrolopyridyl, furoypyridyl, dihydroisoindolyl, tetrahydroquinolynyl and the like.

[0052] Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthroline, acridinyl, phenanthridinyl, xanthenyl and the like.

[0053] In compounds of formula (I), preferred heteroaryl groups include





and the like.

[0054] The term "heterocyclylalkyl" or "heterocycloalkyl" or "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to heterocyclyl groups as defined above linked through a C atom or heteroatom to an alkyl chain.

[0055] The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to an alkyl chain, alkylene, or alkenylene as defined above.

[0056] The term "cyano" as used herein, refers to a -CN group.

[0057] The term "nitro" as used herein, refers to an -NO₂ group.

[0058] The term "hydroxy" as used herein, refers to an -OH group.

[0059] Unless otherwise indicated, when reference is made to a specifically-named aryl (e.g., phenyl), cycloalkyl (e.g., cyclohexyl), heterocyclo (e.g., pyrrolidinyl) or heteroaryl (e.g., imidazolyl), unless otherwise specifically indicated the reference is intended to include rings having 0 to 3, preferably 0-2, substituents selected from those recited above for the aryl, cycloalkyl, heterocyclo and/or heteroaryl groups, as appropriate.

[0060] The term "heteroatoms" shall include oxygen, sulfur and nitrogen.

[0061] The term "carbocyclic" means a saturated or unsaturated monocyclic or bicyclic ring in which all atoms of all rings are carbon. Thus, the term includes cycloalkyl and aryl rings. The carbocyclic ring may be substituted in which case the substituents are selected from those recited above for cycloalkyl and aryl groups.

[0062] When the term "unsaturated" is used herein to refer to a ring or group, the ring or group may be fully unsaturated or partially unsaturated.

[0063] Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds and compounds useful as pharmaceutically-acceptable compounds and/or intermediate compounds useful in making pharmaceutically-acceptable compounds.

[0064] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0065] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.

[0066] The terms pharmaceutically acceptable "salt" and "salts" may refer to basic salts formed with inorganic and organic bases. Such salts include ammonium salts; alkali metal salts, such as lithium, sodium, and potassium salts (which are preferred); alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as amine like salts (e.g., dicyclohexylamine salt, benzathine, N-methyl-D-glucamine, and hydrabamine salts); and salts with amino acids like arginine, lysine, and the like; and zwitterions, the so-called "inner salts." Nontoxic, pharmaceutically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product.

[0067] The term pharmaceutically acceptable "salt" and "salts" also includes acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid, or a hydrohalic acid such as HCl or HBr, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms

which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic, or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric, or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C₁-C₄) alkyl or arylsulfonic acids, which are unsubstituted or substituted, for example by halogen, for example methanesulfonic acid or p-toluenesulfonic acid.

[0068] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985), the disclosure of which is hereby incorporated by reference.

[0069] Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds and compounds useful as pharmaceutically-acceptable compounds and/or intermediate compounds useful in making pharmaceutically-acceptable compounds.

[0070] Any compound that can be converted *in vivo* to provide the bioactive agent (i.e., the compound of formula I) is a prodrug.

[0071] The term "prodrug" denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of the formula, and/or a salt and/or solvate thereof. For example, compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula compounds *per se*. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester *per se* is active, or in those instances where hydrolysis occurs in the blood.

[0072] The term "prodrugs" as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates, and the like.

[0073] Various forms of prodrugs are well known in the art and are described in:


- a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch. 31 (Academic Press, 1996);
- b) Design of Prodrugs, edited by H. Bundgaard (Elsevier, 1985);
- c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch. 5, pp. 113-191 (Harwood Academic Publishers, 1991); and
- d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003).

Said references are incorporated herein by reference.

[0074] Examples of physiologically hydrolyzable esters of compounds of formula (I) include C₁₋₆alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C₁₋₆alkanoyloxy-C₁₋₆alkyl, e.g., acetoxymethyl, pivaloyloxymethyl, or propionyloxymethyl, C₁₋₆alkoxycarbonyloxy-C₁₋₆alkyl, e.g., methoxycarbonyloxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl, and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.


[0075] Prodrug ester examples include the following groups:

(1-alkanoyloxy)alkyl such as




wherein R^z, R^t, and R^y are H, alkyl, aryl, or arylalkyl; however, R^zO cannot be HO.

[0076] Examples of such prodrug esters include



[0077] Other examples of suitable prodrug esters include



wherein R^z can be H, alkyl (such as methyl or *t*-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^v is H, alkyl, halogen or alkoxy, R^u is alkyl, aryl, arylalkyl, or alkoxy, and n_1 is 0, 1, or 2.

[0078] The term "tautomer" refers to compounds of the formula I and salts thereof that may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that the all tautomeric forms, insofar as they may exist, are included within the invention.

[0079] In addition, compounds of the formula I are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% formula I compound ("substantially pure" compound I), which is then used or formulated as described herein. Such "substantially pure" compounds of the formula I are also contemplated herein as part of the present invention.

[0080] All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents and/or exhibit polymorphism. Consequently, compounds of formula I can exist in enantiomeric, or diastereomeric forms, or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.

[0081] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.


[0082] "Therapeutically effective amount" is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to treat or prevent diabetes and/or obesity.

[0083] As used herein, "treating" or "treatment" cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.

SYNTHESIS


[0084] Compounds of formulae Ia and Ib may be prepared as shown in the following reaction schemes and the description thereof, as well as relevant literature procedures that may be used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples. Protection and deprotection in the Schemes below may be carried out by procedures generally known in the art (see, for example, Greene, T.W. et al., Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, publ. (1999)).

[0085] Several different methods of synthesis of amide compounds of formula Ia



are described in Scheme 1. The arylamine II is coupled with heteroaromatic acid chloride IIIa in presence of an amine base (the acid chloride is generated using standard literature conditions, such as treatment of acid IIIb with oxalyl chloride and a catalytic amount of DMF). Alternatively, treatment of carboxylic acid IIIb with cyanuric fluoride provides the intermediate acid fluoride IIIc, which is reacted with arylamine II in the presence of an amine base (Suaifan et al., Tetrahedron, 62:11245-11266 (2006)) to give amide Ia. Finally, a mixture of arylamine II and heteroaromatic acid IIIb can be reacted using standard amide coupling procedures such as BOP/Et₃N, EDCI/HOAt/Et₃N, or DEPBT (Li et al., Org. Lett., 1:91 (1999)) to directly give amide Ia. Within the heteroaromatic ring R¹ and arylamine II depicted in Scheme I and in all subsequent schemes described below, the ring substituents R⁴, R⁵ and R⁶ may be optionally present.


Scheme 1



[0086] The arylamine II and acid chloride IIIa or carboxylic acid IIIb are either commercially available or can be prepared according to standard literature procedures.

[0087] Scheme 3 depicts a general method to synthesize substituted arylamine IIa.

Scheme 3




[0088] Alkylation of bis-phenol 3a with an alkyl halide R³-X^a (where X^a = Cl or Br, or I) in the presence of a base (e.g., K₂CO₃, Cs₂CO₃) provides mono-alkylated bis-phenol 3b. Mitsunobu reaction (e.g., diisopropylazodicarboxylate (DIAD) and PPh₃) of phenol 3b with an alcohol R²-OH affords the unsymmetrical bis-alkylated phenol 3c. Compound 3c is treated with a base (e.g., aqueous NaOH or LiOH) to give carboxylic acid 3d. Curtius rearrangement of acid 3d under

standard conditions (e.g., $(\text{PhO})_2\text{PON}_3$ in the presence of an alcohol R-OH , where R = alkyl or arylalkyl) provides carbamate 3e, which is converted to arylamine IIa by either hydrogenation (when $\text{R} = \text{Bn}$) or a base (e.g., NaOH , where $\text{R} = \text{alkyl}$).

[0089] Alternatively, bis-phenol 3a can be symmetrically bis-alkylated with $\text{R}^3\text{-X}^a$ to afford benzoate ester 3c where $\text{R}^2 = \text{R}^3$. Further transformation according to Scheme 2 provides symmetrical substituted phenyl amine IIa where $\text{R}^2 = \text{R}^3$.


[0090] As shown in Scheme 4, when necessary, phenol 3b can be protected (e.g., TBDPSCI / imidazole, as the TBDPS ether, or $\text{BnBr} / \text{K}_2\text{CO}_3$, as the benzyl ether, etc.) to provide 4c, which is converted to the substituted arylamine IIb via the same sequence previously described to convert 3c to IIa in Scheme 3. A standard coupling reaction (e.g., EDCI / HOBT) between IIb and IIIa or IIIb affords amide 4d. Subsequent deprotection of 4d gives 4e, which can either be alkylated with $\text{R}^2\text{-X}^a$ in the presence of a suitable base (e.g., K_2CO_3 , Cs_2CO_3) or through a Mitsunobu reaction (e.g., DIAD and PPh_3) with an alcohol $\text{R}^2\text{-OH}$ to afford alkylated phenolamide Ic.

Scheme 4




[0091] Another general synthetic route for the preparation of substituted arylamine IIc is shown in Scheme 5.

Scheme 5



[0092] Suzuki coupling reaction (e.g., with $\text{Pd}(\text{PPh}_3)_4$ as catalyst) of bromide 5a with an arylboronic acid provides the biaryl 5b. Dealkylation of the ether with BBr_3 affords phenol 5c. Subsequent alkylation of the phenol 5c with $\text{R}^3\text{-X}^a$ in the presence of a base (e.g., K_2CO_3 , Cs_2CO_3) or via a Mitsunobu reaction (e.g., DIAD and PPh_3) of the phenol 5c with the alcohol $\text{R}^3\text{-OH}$ affords 5d, which is readily converted to amine IIc by reduction of the nitro group (e.g., $\text{H}_2 / \text{Pd-C}$, Fe / HOAc).

[0093] Scheme 6 shows another synthetic sequence for the preparation of the substituted arylamine IId. Compound 6a is converted to phenol 6b through a nucleophilic substitution reaction (e.g., KOH under microwave conditions). Esterification of 6b provides 6c, which is alkylated at the phenolic oxygen with R^3-X in the presence of a base (e.g., K_2CO_3 , Cs_2CO_3) or via a Mitsunobu reaction (e.g., DIAD and PPh_3) of the phenol 6c with an alcohol R^3-OH to afford 6d. Suzuki coupling reaction (e.g., $Pd(PPh_3)_4$ as catalyst) of 6d with an arylboronic acid $R^2-B(OH)_2$ provides 6e. Saponification of the methyl ester 6e affords acid 6f, which is further converted to arylamine IId by a Curtius rearrangement reaction through carbamate 6g followed by deprotection (e.g., by hydrogenolysis with H_2/Pd).



[0094] In each of the aforementioned synthetic methods, when the starting material compound or compound I has an amino group, a carboxyl group, a hydroxyl group or a thiol group, a protecting group generally used in peptide chemistry or those generally known in the art (see, for example, Greene, T.W. et al., *Protecting Groups in Organic Synthesis*, 3rd Edition, Wiley, publ. (1999)) may be introduced into these groups. In addition, the protecting group can be removed according to a conventional method in any step of each reaction scheme.

UTILITIES AND COMBINATIONS

A. Utilities

[0095] The compounds of the present invention possess activity as enhancers of activity of the enzyme glucokinase, and, therefore, may be used in the treatment of diseases associated with glucokinase activity.

[0096] Accordingly, the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating, preventing, or slowing

the progression of diabetes and related conditions, microvascular complications associated with diabetes, macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, and other maladies. Consequently, it is believed that the compounds of the present invention may be used in preventing, inhibiting, or treating diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, and glaucoma.

[0097] Metabolic Syndrome or "Syndrome X" is described in Ford, et al., J. Am. Med. Assoc., 287:356-359 (2002) and Arbeen et al., Curr. Med. Chem. - Imm., Endoc. & Metab. Agents, 1:1-24 (2001).

B. Combinations

[0098] The present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent. Optionally, compounds of the present invention can be used alone, in combination with other compounds of the invention, or in combination with one or more other therapeutic agent(s), e.g., an antidiabetic agent or other pharmaceutically active material.

[0099] The compounds of the present invention may be employed in combination with other enhancers of activity of glucokinase or one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-infective agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-ischemic agents, anti-cancer agents, anti-cytotoxic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, appetite suppressants, memory enhancing agents, and cognitive agents.

[0100] Examples of suitable anti-diabetic agents for use in combination with the compounds of the present invention include insulin and insulin analogs: LysPro insulin, inhaled formulations comprising insulin; glucagon-like peptides; sulfonylureas and analogs: chlorpropamide, glibenclamide, tolbutamide, tolazamide, acetohexamide, glypizide, glyburide, glimepiride, repaglinide, meglitinide; biguanides: metformin, phenformin, buformin; alpha2-antagonists and imidazolines: midaglizole, isaglidole, deriglidole, idazoxan, efaroxan, fluparoxan; other insulin secretagogues: linoglitazone, insulinotropan, exendin-4, BTS-67582, A-4166; thiazolidinediones (PPARgamma agonists): ciglitazone, pioglitazone, troglitazone, rosiglitazone; non-thiazolidinedione PPAR-gamma agonists; selective PPARgamma modulators (SPPARMs; e.g., metaglidase from Metabolex); PPAR-alpha agonists; PPAR alpha/gamma dual agonists; PPAR delta agonists, PPARalpha/gamma/delta pan agonists; SGLT2 inhibitors; dipeptidyl peptidase-IV (DPP4) inhibitors; aldose reductase inhibitors; RXR agonists: JTT-501, MX-6054, DRF2593, LG100268; fatty acid oxidation inhibitors: clomoxir, etomoxir; alpha-glucosidase inhibitors: precose, acarbose, miglitol, emiglitate, voglibose, MDL-25,637, camiglibose, MDL-73,945; beta-agonists: BRL 35135, BRL 37344, Ro 16-8714, ICI D7114, CL 316,243, TAK-667, AZ40140; phosphodiesterase inhibitors, both cAMP and cGMP type: sildenafil, L686398: L-386,398; amylin antagonists: pramlintide, AC-137; lipoxigenase inhibitors: masoprocol; somatostatin analogs: BM-23014, seglitide, octreotide; glucagon antagonists: BAY 276-9955; insulin signaling agonists, insulin mimetics, PTP1B inhibitors: L-783281, TER17411, TER17529; gluconeogenesis inhibitors: GP3034; somatostatin analogs and antagonists; antilipolytic agents: nicotinic acid, acipimox, WAG 994; glucose transport stimulating agents: BM-130795; glucose synthase kinase inhibitors: lithium chloride, CT98014, CT98023; and galanin receptor agonists.

[0101] Other suitable thiazolidinediones include Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Wellcome's farglitazar (GI-262570), englitazone (CP-68722, Pfizer), or darglitazone (CP-86325, Pfizer), isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 or balaglitazone (Dr. Reddy/NN), or YM-440 (Yamanouchi).

[0102] Suitable PPAR α/γ dual agonists include muraglitazar (Bristol-Myers Squibb), tesaglitazar (Astra/Zeneca), naveglitazar (Lilly/Ligand); AVE-0847 (Sanofi-Aventis); TAK-654 (Takeda), as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor α (PPAR α) and PPAR γ ; Effect of PPAR α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes, 47:1841-1847 (1998), WO 01/21602 and U.S. Patent No. 6,414,002, the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are preferred for use herein. Suitable PPAR δ agonists include, for example, GW-501516 (Glaxo). Suitable PPAR $\alpha/\gamma/\delta$ pan agonists include, for example, GW-677954 (Glaxo).

[0103] Suitable $\alpha 2$ antagonists also include those disclosed in WO 00/59506, employing dosages as set out herein.

[0104] Suitable SGLT2 inhibitors include dapagliflozin (Bristol-Myers Squibb), sergiflozin (Glaxo SmithKline), T-1095, phlorizin, WAY-123783, and those described in WO 01/27128.

[0105] Suitable DPP4 inhibitors include saxagliptin (Bristol-Myers Squibb), vildagliptin (Novartis) and sitagliptin (Merck) as well as those disclosed in WO 99/38501, WO 99/46272, WO 99/67279 (PROBIODRUG), WO 99/67278 (PROBIODRUG), WO 99/61431 (PROBIODRUG), NVP-DPP728A (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine) (Novartis) as disclosed by Hughes et al., *Biochemistry*, 38(36):11597-11603 (1999), TSL-225 (tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) as disclosed by Yamada et al., *Bioorg. & Med. Chem. Lett.*, 8: 1537-1540 (1998), 2-cyanopyrrolidides and 4-cyanopyrrolidides, as disclosed by Ashworth et al., *Bioorg. & Med. Chem. Lett.*, 6(22):1163-1166 and 2745-2748 (1996), employing dosages as set out in the above references.

[0106] Suitable aldose reductase inhibitors include those disclosed in WO 99/26659.

[0107] Suitable meglitinides include nateglinide (Novartis) or KAD 1229 (PF/Kissei).

[0108] Examples of glucagon-like peptide-1 (GLP-1) include GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener), as well as AC2993 (Amylin), and LY-315902 (Lilly).

[0109] Other anti-diabetic agents that can be used in combination with compounds of the invention include ergoset and D-chiroinositol.

[0110] Suitable anti-ischemic agents include, but are not limited to, those described in the Physicians' Desk Reference and NHE inhibitors, including those disclosed in WO 99/43663.

[0111] Examples of suitable anti-infective agents are antibiotic agents, including, but not limited to, those described in the Physicians' Desk Reference.

[0112] Examples of suitable lipid lowering agents for use in combination with the compounds of the present invention include one or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, cholesterol ester transfer protein inhibitors (e.g., torcetrapib (Pfizer)), and/or nicotinic acid and derivatives thereof.

[0113] MTP inhibitors which may be employed as described above include those disclosed in U.S. Patent Nos. 5,595,872, 5,739,135, 5,712,279, 5,760,246, 5,827,875, 5,885,983, and 5,962,440.

[0114] The HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of formula I include mevastatin and related compounds, as disclosed in U.S. Patent No. 3,983,140, lovastatin, (mevinolin) and related compounds, as disclosed in U.S. Patent No. 4,231,938, pravastatin, and related compounds, such as disclosed in U.S. Patent No. 4,346,227, simvastatin, and related compounds, as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772; cerivastatin, as disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080; atorvastatin, as disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929, and 5,686,104; atavastatin (Nissan/Sankyo's nisvastatin (NK-104)), as disclosed in U.S. Patent No. 5,011,930; visastatin (Shionogi-Astra/Zeneca (ZD-4522)) as disclosed in U.S. Patent No. 5,260,440; and related statin compounds disclosed in U.S. Patent No. 5,753,675; pyrazole analogs of mevalonolactone derivatives, as disclosed in U.S. Patent No. 4,613,610; indene analogs of mevalonolactone derivatives, as disclosed in PCT application WO 86/03488; 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives thereof, as disclosed in U.S. Patent No. 4,647,576; Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate; imidazole analogs of mevalonolactone, as disclosed in PCT application WO 86/07054; 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, as disclosed in French Patent No. 2,596,393; 2,3-disubstituted pyrrole, furan and thiophene derivatives, as disclosed in European Patent Application No. 0221025; naphthyl analogs of mevalonolactone, as disclosed in U.S. Patent No. 4,686,237; octahydronaphthalenes, such as disclosed in U.S. Patent No. 4,499,289; keto analogs of mevinolin (lovastatin), as disclosed in European Patent Application No. 0142146 A2; and quinoline and pyridine derivatives, as disclosed in U.S. Patent Nos. 5,506,219 and 5,691,322.

[0115] Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin, and ZD-4522.

[0116] In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase, such as those disclosed in GB 2205837, are suitable for use in combination with the compounds of the present invention.

[0117] The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al., *J. Med. Chem.*, 31(10):1869-1871 (1988), including isoprenoid (phosphinyl-methyl)phosphonates, as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A. et al., *Current Pharmaceutical Design*, 2:1-40 (1996).

[0118] In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by Ortiz de Montellano, P. et al, *J. Med. Chem.*, 20:243-249 (1977), the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey et al., *J. Am. Chem. Soc.*, 98:1291-1293 (1976), phosphinylphosphonates reported by McClard, R.W. et al, *J. Am. Chem. Soc.*, 109:5544 (1987) and cyclopropanes reported by Capson, T.L., Ph.D., dissertation, June 1987, Dept. Med. Chem. U. of Utah, Abstract, Table of Contents,

pp. 16, 17, 40-43, 48-51, Summary.

[0119] The fibric acid derivatives which may be employed in combination with one or more compounds of formula I include fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate, and the like, probucol, and related compounds, as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants, such as cholestyramine, colestipol and DEAE-Sephadex (Sechalex®, Policexide®), as well as lipostabil (Rhône-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmas-tanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea deriva-tives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives, such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes, such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

[0120] The ACAT inhibitor which may be employed in combination with one or more compounds of formula I include those disclosed in *Drugs of the Future*, 24:9-15 (1999), (Avasimibe); Nicolosi et al., "The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", *Atherosclerosis*, (Shannon, Irel.), 137 (1):77-85 (1998); Ghiselli, G., "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB 100-containing lipoprotein", *Cardiovasc. Drug Rev.*, 16(1):16-30 (1998); Smith, C. et al., "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", *Bioorg. Med. Chem. Lett.*, 6(1):47-50 (1996); Krause, B.R. et al., Chapter 6: "ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals", *Inflammation: Mediators and Pathways*, CRC Press, Inc., publ., Ruffolo, Jr., R.R. et al., eds., pp. 173-198 (1995); Sliskovic et al., "ACAT inhibitors: potential anti-atherosclerotic agents", *Curr. Med. Chem.*, 1(3):204-225 (1994); Stout et al., "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-(1-phenylcyclopentyl)methylureas with enhanced hypocholesterolemic activity", *Chemtracts: Org. Chem.*, 8(6):359-362 (1995), or TS-962 (Taisho Pharmaceutical Co. Ltd.).

[0121] The hypolipidemic agent may be an upregulator of LD2 receptor activity, such as MD-700 (Taisho Pharmaceu-tical Co. Ltd) and LY295427 (Eli Lilly).

[0122] Examples of suitable cholesterol absorption inhibitors for use in combination with the compounds of the invention include SCH48461 (Schering-Plough), as well as those disclosed in *Atherosclerosis*, 115:45-63 (1995) and *J. Med. Chem.*, 41:973 (1998).

[0123] Examples of suitable ileal Na⁺/bile acid cotransporter inhibitors for use in combination with the compounds of the invention include compounds as disclosed in *Drugs of the Future*, 24:425-430 (1999).

[0124] The lipoyxygenase inhibitors which may be employed in combination with one or more compounds of formula I include 15-lipoyxygenase (15-LO) inhibitors, such as benzimidazole derivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as disclosed in WO 97/12613, isothiazolones, as disclosed in WO 96/38144, and 15-LO inhibitors, as disclosed by Sendobry et al., "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoyxygenase inhibitor lacking significant antioxidant properties", *Brit. J. Pharmacology*, 120:1199-1206 (1997), and Cornicelli et al., "15-Lipox-ygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", *Current Pharmaceutical Design*, 5:11-20 (1999).

[0125] Examples of suitable anti-hypertensive agents for use in combination with the compounds of the present in-vention include beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g., diltiazem, verapamil, nifed-ipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisi-nopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan, and compounds disclosed in U.S. Patent Nos. 5,612,359 and 6,043,265), Dual ET/All antagonist (e.g., com-pounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates.

[0126] Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor I antagonist or inverse agonist, a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta drug, and/or an anorectic agent.

[0127] Cannabinoid receptor 1 antagonists and inverse agonists which may be optionally employed in combination with compounds of the present invention include rimonabant, SLV 319, and those discussed in Hertzog, D.L., *Expert Opin. Ther. Patents*, 14:1435-1452 (2004).

[0128] The beta 3 adrenergic agonists which may be optionally employed in combination with compounds of the present invention include AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer,) or other known beta 3 agonists, as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983, and 5,488,064, with AJ9677,

L750,355, and CP331648 being preferred.

[0129] Examples of lipase inhibitors which may be optionally employed in combination with compounds of the present invention include orlistat or ATL-962 (Alizyme), with orlistat being preferred.

[0130] The serotonin (and dopamine) reuptake inhibitor which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson), or axokine (Regeneron), with sibutramine and topiramate being preferred.

[0131] Examples of thyroid receptor beta compounds which may be optionally employed in combination with compounds of the present invention include thyroid receptor ligands, such as those disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio), and WO 00/039077 (KaroBio), with compounds of the KaroBio applications being preferred.

[0132] The anorectic agent which may be optionally employed in combination with compounds of the present invention include dexamphetamine, phentermine, phenylpropanolamine, or mazindol, with dexamphetamine being preferred.

[0133] Other compounds that can be used in combination with the compounds of the present invention include CCK receptor agonists (e.g., SR-27895B); galanin receptor antagonists; MCR-4 antagonists (e.g., HP-228); leptin or mimentics; 11-beta-hydroxysteroid dehydrogenase type-1 inhibitors; urocortin mimetics, CRF antagonists, and CRF binding proteins (e.g., RU-486, urocortin).

[0134] Further, the compounds of the present invention may be used in combination with anti-cancer and cytotoxic agents, including but not limited to alkylating agents such as nitrogen mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and triazines; antimetabolites such as folate antagonists, purine analogues, and pyrimidine analogues; antibiotics such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes such as L-asparaginase; farnesyl-protein transferase inhibitors; 5 α reductase inhibitors; inhibitors of 17 β -hydroxy steroid dehydrogenase type 3; hormonal agents such as glucocorticoids, estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, octreotide acetate; microtubule-disruptor agents, such as ecteinascidins or their analogs and derivatives; microtubule-stabilizing agents such as taxanes, for example, paclitaxel (Taxol®), docetaxel (Taxotere®), and their analogs, and epothilones, such as epothilones A-F and their analogs; plant-derived products, such as vinca alkaloids, epipodophyllotoxins, taxanes; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and miscellaneous agents such as hydroxyurea, procarbazine, mitotane, hexamethylmelamine, platinum coordination complexes such as cisplatin and carboplatin; and other agents used as anti-cancer and cytotoxic agents such as biological response modifiers, growth factors; immune modulators; and monoclonal antibodies. Additional anti-cancer agents are disclosed in EP 1177791. The compounds of the invention may also be used in conjunction with radiation therapy.

[0135] Examples of suitable memory enhancing agents, anti-dementia agents, or cognitive agents for use in combination with the compounds of the present invention include, but are not limited to, donepezil, rivastigmine, galantamine, memantine, tacrine, metrifonate, muscarine, xanomelline, deprenyl, and physostigmine.

[0136] The aforementioned patents and patent applications are incorporated herein by reference.

[0137] The above other therapeutic agents, when employed in combination with the compounds of the present invention may be used, for example, in those amounts indicated in the Physicians' Desk Reference, as in the patents set out above, or as otherwise determined by one of ordinary skill in the art.

[0138] The compounds of formula I can be administered for any of the uses described herein by any suitable means, for example, orally, such as in the form of tablets, capsules, granules, or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.

[0139] In carrying out the method of the invention for treating diabetes and related diseases, a pharmaceutical composition will be employed containing the compounds of formula I, with or without other antidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or other type therapeutic agents in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders, and the like. The compounds can be administered to a mammalian patient, including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, beads, granules, or powders. The dose for adults is between 0.5 and 2,000 mg per day, preferably between 1 and 500 mg, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.

[0140] A typical capsule for oral administration contains compounds of structure 1 (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

[0141] A typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

EXAMPLES

[0142] The following working Examples serve to better illustrate, but not limit, some of the preferred embodiments of the present invention.

GENERAL

[0143] The term HPLC refers to an analytical Shimadzu high performance liquid chromatograph using one of following methods:

Method A: YMC or Phenomenex C18 5 μ m 4.6 X 50mm column; 4 min continuous gradient from 0 to 100%, then hold at 100% solvent B for 1 minute; where A = 10% MeOH:90% H₂O:0.2% H₃PO₄ and B = 90% MeOH:10% H₂O:0.2% H₃PO₄; flow rate = 4 mL/min, UV detection at 220 nm.

Method B: Zorbax SB C18 5 μ m 4.6x75mm column; 8 min continuous gradient of 50% solvent A:B to 100% B, then hold at 100% solvent B for 2 minute; where A = 10% MeOH +90% H₂O + 0.2% H₃PO₄, and B = 90% MeOH + 10% H₂O + 0.2% H₃PO₄; flow rate = 2.5 mL/min, UV detection at 220 nm.

LCMS Method A: ESI, positive ion spectrum; Phenomenex ODS S5 4.6 x 50 mm column; UV detection at 220 nm; flow rate= 4 mL/min; 4 min continuous gradient from 100% A to 100% B, where A = 10%MeOH: 90%H₂O:0.1 % TFA, and B=90%MeOH: 10%H₂O:0.1% TFA

LCMS Method B: ESI, positive and negative ion spectra; Phenomenex Luna C18 4.6 x 50 mm column; UV detection at 220 nm; flow rate = 4 mL/min; 4 min continuous gradient from 100% A to 100% B, where A = 10:90:MeCN : H₂O (containing 10 mM NH₄Ac), and B = 90:10 CH₃CN : H₂O (containing 10 mM NH₄Ac).

[0144] Preparative (prep) HPLC was carried out with an automated Shimadzu HPLC system using a continuous of solvent A (10% MeOH/90%H₂O/0.2%TFA) vs solvent B (90% MeOH/10%H₂O/0.2% TFA). The preparative columns are packed with YMC or Phenomenex ODS C 18, 5 micron resin or equivalent.

ABBREVIATIONS

[0145] The following abbreviations are employed in the Examples and elsewhere herein:

Ph = phenyl

Bn = benzyl

i-Bu = iso-butyl

Me = methyl

Et = ethyl

Pr = propyl

Bu = butyl

AIBN = 2,2'-Azobisisobutyronitrile

TMS = trimethylsilyl

TMSCHN₂ = (trimethylsilyl)diazomethane

Fmoc = fluorenylmethoxycarbonyl

Boc or BOC = *tert*-butoxycarbonyl

Cbz = carbobenzyloxy or carbobenzoxo or benzyloxycarbonyl

HOAc or AcOH = acetic acid

TBDPSCI = *tert*-butylchlorodiphenylsilane

TMSI = iodotrimethylsilane

DCM = dichloromethane

DEPBT = 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4[3H]-one

DIEA = N,N-diisopropylethylamine

DMA = N,N-dimethylacetamide

DMF = N,N-dimethylformamide

DMSO = dimethylsulfoxide

EtOAc = ethyl acetate

K₂CO₃ = potassium carbonate

NaHCO₃ = sodium bicarbonate

THF = tetrahydrofuran

TFA = trifluoroacetic acid

mCPBA = 3-Chloroperoxybenzoic acid

NMM = N-methyl morpholine

NBS = N-Bromosuccinimide

DIAD = Diisopropyl azodicarboxylate

DEAD = Diethyl azodicarboxylate

n-BuLi = n-butyllithium

Oxone® = Monopersulfate

Pd/C = palladium on carbon

PtO₂ = platinum oxide

H₂O = water

TEA = triethylamine

EDAC = 3-ethyl-3'-(dimethylamino)propyl-carbodiimide hydrochloride (or 1-[(3-(dimethylamino)propyl)]-3-ethylcarbodiimide hydrochloride)

HOBT or HOBT·H₂O = 1-hydroxybenzotriazole hydrate

HOAT = 1-hydroxy-7-azabenzotriazole

PyBOP reagent = benzotriazol-1-yloxy-tripyrrolidino phosphonium hexafluorophosphate

BOP = benzotriazol-1-yloxy-tris(dimethylamino) phosphonium hexafluorophosphate

equiv = equivalent(s)

min = minute(s)

h or hr = hour(s)

L = liter

mL = milliliter

μL = microliter

g = gram(s)

mg = milligram(s)

mol = mole(s)

mmol = millimole(s)

meq = milliequivalent

RT or R.T. = room temperature

sat or sat'd = saturated

aq. = aqueous

TLC = thin layer chromatography

UV = ultraviolet

HPLC = high performance liquid chromatography

HPLC t_R = HPLC retention time

LC/MS = high performance liquid chromatography/mass spectrometry

MS or Mass Spec = mass spectrometry

NMR = nuclear magnetic resonance


mp = melting point

PXPd₂ = Dichloro(chlorodi-*tert*-butylphosphine)palladium (II) dimer or [PdCl₂(*t*-Bu)₂PCl]₂


[0146] The following Examples are illustrative of preferred embodiments of the invention.

EXAMPLE 1

[0147]




A.




[0148] To a RT solution of (S)-3-(1-methoxypropan-2-yloxy)-5-(4-(methylsulfonyl)phenoxy) benzoic acid¹ (2 g, 5.26 mmol) in 1,4-dioxane (25 mL) were successively added PhCH₂OH (0.66 mL, 6.31 mmol), Et₃N (1.03 mL, 7.36 mmol) and (PhO)₂PON₃ (1.37 mL, 6.31 mmol). The reaction mixture was stirred at 120°C overnight. Volatiles were removed *in vacuo* and the residue was chromatographed ((SiO₂; 80 g; continuous gradient from 100% hex to 50:50 hex:EtOAc for 40 min, then hold for 20 min) to give Part A compound (2.12 g, 83% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.90 (d, *J*=9.2 Hz, 2 H), 7.27 - 7.40 (m, 5 H), 7.14 (d, *J*=8.8 Hz, 2 H), 6.96 (s, 1 H), 6.86 (s, 1 H), 6.35 (t, *J*=2.2 Hz, 1 H), 5.14 (s, 2 H), 4.49 - 4.56 (m, 1 H), 3.44 - 3.55 (m, 2 H), 3.36 (s, 3 H), 3.09 (s, 3 H), 1.25 (d, *J*=6.2 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 486, *t_R* = 3.50 min.

B.



[0149] To a solution of Part A Compound (2.11 g, 4.35 mmol) in MeOH (30 mL) was added 10% Pd/C (0.211 g) under Ar at RT with vigorous stirring. The reaction was stirred under 1 atmosphere of H₂ for 1 h, then was filtered through a plug of Celite®. The filtrate was concentrated *in vacuo* to give Part B Compound (1.52 g, 100%) as a beige sticky oil. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 352, *t_R* = 2.17 min.


C.



[0150] To a RT solution of Part B compound (40 mg, 0.114 mmol) in CH₂Cl₂ (1.5 mL) was added 1,3-thiazole-2-carbonyl chloride (27 mg, 0.185 mmol) followed by Et₃N (59 μL; 0.426 mmol). The reaction mixture was stirred at RT for 2 h, then was diluted with EtOAc (100 mL), washed with H₂O (10 mL) and brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was chromatographed (SiO₂; 12 g; continuous gradient from 100% hex to 1:4 hex:EtOAc over 25 min, then held at 1:4 hex:EtOAc for 5 min) to give Part C compound (63 mg, 96% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 9.09 (s, 1 H), 7.87 - 7.92 (m, 3 H), 7.64 (d, *J*=3.3 Hz, 1 H), 7.21 (s, 1 H), 7.13 (d, *J*=8.8 Hz, 2 H), 7.08 (s, 1 H), 6.47 (s, 1 H), 4.52 - 4.59 (m, 1 H), 3.54 - 3.59 (m, 1 H), 3.47 - 3.52 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 1.32 (d, *J*=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 463, *t_R* = 3.23 min.

EXAMPLES 2 TO 5

[0151] Examples 2 to 5 were prepared using the same general procedure as described for the synthesis of Example 1 from Example 1 Part B compound and an appropriate acid chloride




IIIa

The structures of Examples 1 to 5 and their spectral characterization are shown in Table 1.

TABLE 1


Example No.	Structure	¹ H NMR, (M + H)/z, LCMS t _R
1		¹ H NMR (500 MHz, CDCl ₃) δ ppm 9.09 (s, 1 H), 7.87 - 7.92 (m, 3 H), 7.64 (d, J=3.3 Hz, 1 H), 7.21 (s, 1 H), 7.13 (d, J=8.8 Hz, 2 H), 7.08 (s, 1 H), 6.47 (s, 1 H), 4.52 - 4.59 (m, 1 H), 3.54 - 3.59 (m, 1 H), 3.47 - 3.52 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 1.32 (d, J=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 463, t _R = 3.23 min.
2		¹ H NMR (400 MHz, CDCl ₃) δ ppm 10.13 (s, 1 H), 8.61 (d, J=4.0 Hz, 1 H), 8.28 (d, J=7.9 Hz, 1 H), 7.91 - 7.97 (m, 1 H), 7.88 (d, J=9.2 Hz, 2 H), 7.52 (dd, J=6.6, 4.8 Hz, 1 H), 7.30 - 7.33 (m, 1 H), 7.16 - 7.20 (m, 1 H), 7.13 (d, J=8.8 Hz, 2 H), 6.46 (t, J=2.2 Hz, 1 H), 4.53 - 4.62 (m, 1 H), 3.55 - 3.61 (m, 1 H), 3.47 - 3.52 (m, 1 H), 3.41 (s, 3 H), 3.05 (s, 3 H), 1.33 (d, J=6.2 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 457, t _R = 3.28 min.
3		¹ H NMR (500 MHz, CDCl ₃) δ ppm 9.66 (s, 1 H), 9.48 (s, 1 H), 8.82 (d, J=2.2 Hz, 1 H), 8.58 (s, 1 H), 7.89 (d, J=8.8 Hz, 2 H), 7.29 (s, 1 H), 7.11 - 7.16 (m, J=8.8 Hz, 3 H), 6.48 (s, 1 H), 4.54 - 4.61 (m, 1 H), 3.58 (dd, J=10.4, 6.0 Hz, 1 H), 3.48 - 3.52 (m, 1 H), 3.41 (s, 3 H), 3.06 (s, 3 H), 1.33 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 458, t _R = 3.08 min.
4		¹ H NMR (500 MHz, CDCl ₃) δ ppm 8.65 (s, 1 H), 7.87 (d, J=8.8 Hz, 2 H), 7.22 (s, 1 H), 7.12 (d, J=8.8 Hz, 2 H), 7.04 (s, 1 H), 6.59 (s, 1 H), 6.41 (s, 1 H), 4.51 - 4.59 (m, 1 H), 3.81 (s, 3 H), 3.53 - 3.60 (m, 1 H), 3.46 - 3.51 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 2.30 (s, 3 H), 1.32 (d, J=6.0 Hz, 3 H); LCMS Method B (ESI, pos./neg. ion spectrum): (M+H)/z = 474, t _R = 3.04 min.

(continued)


Example No.	Structure	^1H NMR, (M + H)/z, LCMS t_R
5		^1H NMR (500 MHz, CDCl_3) δ ppm 9.25 (s, 1 H), 8.11 (d, $J=8.2$ Hz, 1 H), 8.00 (d, $J=8.2$ Hz, 1 H), 7.90 (d, $J=8.8$ Hz, 2 H), 7.59 (t, $J=7.1$ Hz, 1 H), 7.53 (t, $J=7.4$ Hz, 1 H), 7.29 (s, 1 H), 7.11 - 7.17 (m, 3 H), 6.50 (s, 1 H), 4.54 - 4.62 (m, 1 H), 3.56 - 3.61 (m, 1 H), 3.49 - 3.53 (m, 1 H), 3.41 (s, 3 H), 3.06 (s, 3 H), 1.34 (d, $J=6.6$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 513, t_R = 3.69 min.

EXAMPLE 6

[0152]




A.




[0153] To a RT solution of 1H-imidazole-4-carboxylic acid (1.12 g, 9.99 mmol) in pyridine (15 mL) and DMF (30 mL) was added triphenylmethyl chloride (3.06 g, 11.0 mmol). The reaction mixture was stirred at RT overnight, then was partitioned between EtOAc (500 mL) and H_2O (50 mL). The organic phase was washed with H_2O (20 mL), 10% citric acid (20 mL) and brine (5 mL), dried (MgSO_4) and concentrated *in vacuo*. The residue was triturated with EtOAc to afford 1-trityl-1H-imidazole-4-carboxylic acid (2.78 g, 79% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = not observed, t_R = 3.27 min.

B.



[0154] BOP (503 mg, 1.14 mmol) was added to a RT solution of Part A compound (403 mg, 1.14 mmol) in CH_2Cl_2 (5 mL), followed by Et_3N (0.32 mL; 2.28 mmol). After stirring at RT for 10 min, Example 1 Part A compound (200 mg, 0.569 mmol) was added. The reaction was stirred at RT for 72 h; LCMS indicated complete consumption of Example 1 Part A compound. The crude Part B compound was directly used in the next step without further purification. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = not observed, t_R = 3.47 min.


C.



[0155] TFA (5 mL) was added to the crude Part B compound and the mixture was stirred at RT for 10 min. Volatiles were removed *in vacuo* and the residue was chromatographed (SiO₂; 40 g; continuous gradient from 100:0 hex:EtOAc to 0: 100 hex:EtOAc over 30 min, then held at 100% EtOAc for 20 min) to give the title compound (215 mg, 85% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 7.93 (d, *J*=8.8 Hz, 2 H), 7.77 (s, 2 H), 7.25 (s, 1 H), 7.20 (d, *J*=8.8 Hz, 2 H), 7.16 (s, 1 H), 6.45 - 6.47 (m, 1 H), 4.56 - 4.61 (m, 1 H), 3.54 - 3.58 (m, 1 H), 3.49 - 3.53 (m, 1 H), 3.38 (s, 3 H), 3.11 (s, 3 H), 1.29 (d, *J*=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 446, *t_R* = 2.57 min.

EXAMPLES 7 TO 20

[0156] Examples 7 to 20 were prepared using the same general procedure as described for the synthesis of Example 6 Part B Compound from Example 6 Part A Compound and an appropriate carboxylic acid IIIb (Scheme 1)








**IIIb**

[0157] The structures of Examples 7 to 20 and their spectral characterization are shown in Table 2.






TABLE 2

Example No.	Structure	¹ H NMR, (M + H)/ <i>z</i> , LCMS <i>t_R</i>
7		¹ H NMR (500 MHz, CDCl ₃ /CD ₃ OD) δ ppm 8.14 (s, 1 H), 7.86 (d, <i>J</i> =8.8 Hz, 2 H), 7.17 (s, 1 H), 7.08 - 7.13 (m, 3 H), 6.44 (s, 1 H), 4.52 (dd, <i>J</i> =10.4, 6.0 Hz, 1 H), 3.52 - 3.58 (m, 1 H), 3.44 - 3.49 (m, 1 H), 3.38 (s, 3 H), 3.03 (s, 3 H), 1.29 (d, <i>J</i> =6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/ <i>z</i> = 447, <i>t_R</i> = 2.80 min.
8		¹ H NMR (500 MHz, CDCl ₃) δ ppm 8.77 (s, 1 H), 7.87 (d, <i>J</i> =8.8 Hz, 2 H), 7.62 (d, <i>J</i> =2.2 Hz, 1 H), 7.21 (s, 1 H), 7.12 (d, <i>J</i> =8.8 Hz, 2 H), 7.04 (s, 1 H), 6.92 (d, <i>J</i> =2.2 Hz, 1 H), 6.42 (s, 1 H), 4.51 - 4.60 (m, 1 H), 3.55 - 3.61 (m, 1 H), 3.47 - 3.53 (m, 1 H), 3.41 (s, 3 H), 3.05 (s, 3 H), 1.31 (d, <i>J</i> =6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/ <i>z</i> = 446, <i>t_R</i> = 2.97 min.

(continued)


Example No.	Structure	^1H NMR, (M + H) $^+$ /z, LCMS t_R
9		^1H NMR (500 MHz, CDCl_3) δ ppm 10.13 (s, 1 H), 7.85 - 7.91 (m, 3 H), 7.18 - 7.23 (m, 2 H), 7.11 - 7.15 (m, 3 H), 7.03 (d, $J=8.2$ Hz, 1 H), 6.42 (s, 1 H), 5.97 (s, 2 H), 4.52 - 4.60 (m, 1 H), 3.58 (dd, $J=10.2$, 5.8 Hz, 1 H), 3.46 - 3.52 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 1.32 (d, $J=6.0$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 472, t_R = 3.35 min.
10		^1H NMR (400 MHz, CD_3OD) δ ppm 7.95 (s, 1 H), 7.81 (d, $J=8.8$ Hz, 2 H), 7.28 (s, 1 H), 7.13 (d, $J=1.8$ Hz, 2 H), 7.07 (d, $J=8.8$ Hz, 2 H), 6.38 - 6.41 (m, 1 H), 4.44 - 4.54 (m, 1 H), 3.49 - 3.55 (m, 1 H), 3.42 - 3.48 (m, 1 H), 3.35 (s, 3 H), 3.01 (s, 3 H), 2.60 (s, 3 H), 1.25 (d, $J=6.2$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 460, t_R = 2.55 min.
11		^1H NMR (400 MHz, CDCl_3) δ ppm 9.20 (s, 1 H), 8.04 (s, 1 H), 7.88 (d, $J=8.8$ Hz, 2 H), 7.27 - 7.40 (m, 5 H), 7.13 (d, $J=8.8$ Hz, 2 H), 7.09 (s, 1 H), 6.45 (t, $J=2.2$ Hz, 1 H), 4.51 - 4.62 (m, 1 H), 4.33 (s, 2 H), 3.54 - 3.61 (m, 1 H), 3.46 - 3.52 (m, 1 H), 3.41 (s, 3 H), 3.05 (s, 3 H), 1.33 (d, $J=6.2$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 553, t_R = 3.70 min.
12		^1H NMR (400 MHz, CDCl_3) δ ppm 9.27 (s, 1 H), 8.80 (d, $J=2.2$ Hz, 1 H), 8.27 (d, $J=2.2$ Hz, 1 H), 7.88 (d, $J=8.8$ Hz, 2 H), 7.22 (s, 1 H), 7.13 (d, $J=8.8$ Hz, 2 H), 7.09 (s, 1 H), 6.45 (s, 1 H), 4.52 - 4.61 (m, 1 H), 3.55 - 3.61 (m, 1 H), 3.48 - 3.53 (m, 1 H), 3.41 (s, 3 H), 3.05 (s, 3 H), 1.32 (d, $J=6.6$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 463, t_R = 3.10 min.
13		^1H NMR (500 MHz, CDCl_3) δ ppm 9.00 (s, 1 H), 8.09 (s, 1 H), 7.88 (d, $J=8.8$ Hz, 2 H), 7.50 (d, $J=4.4$ Hz, 1 H), 7.22 (s, 1 H), 7.09 - 7.16 (m, 3 H), 6.98 (d, $J=4.9$ Hz, 1 H), 6.41 - 6.45 (m, 1 H), 4.51 - 4.60 (m, 1 H), 3.55 - 3.60 (m, 1 H), 3.47 - 3.52 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 1.32 (d, $J=6.0$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 502, t_R = 3.18 min.
14		^1H NMR (500 MHz, CDCl_3) δ ppm 9.24 (s, 1 H), 8.14 - 8.20 (m, 2 H), 7.89 (d, $J=8.8$ Hz, 2 H), 7.59 (d, $J=8.8$ Hz, 1 H), 7.26 - 7.32 (m, 2 H), 7.11 - 7.17 (m, 3 H), 6.89 (t, $J=6.3$ Hz, 1 H), 6.42 - 6.47 (m, 1 H), 4.52 - 4.61 (m, 1 H), 3.55 - 3.61 (m, 1 H), 3.47 - 3.53 (m, 1 H), 3.41 (s, 3 H), 3.06 (s, 3 H), 1.33 (d, $J=6.0$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 496, t_R = 2.76 min.
15		^1H NMR (500 MHz, CDCl_3) δ ppm 9.90 (s, 1 H), 8.47 (s, 1 H), 7.84 - 7.91 (m, 3 H), 7.08 - 7.16 (m, 4 H), 6.47 (s, 1 H), 4.52 - 4.60 (m, 1 H), 3.97 (s, 3 H), 3.58 - 3.64 (m, 1 H), 3.52 - 3.57 (m, 1 H), 3.43 (s, 3 H), 3.05 (s, 3 H), 1.30 (d, $J=6.0$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) $^+$ /z = 460, t_R = 2.57 min.

(continued)

Example No.	Structure	¹ H NMR, (M + H) ⁺ /z, LCMS t _R
16		¹ H NMR (500 MHz, CDCl ₃) δ ppm 10.01 (s, 1 H), 9.18 (s, 1 H), 8.48 - 8.53 (m, 1 H), 8.33 (d, J=8.2 Hz, 1 H), 7.89 (d, J=8.8 Hz, 2 H), 7.30 (s, 1 H), 7.17 (s, 1 H), 7.14 (d, J=9.3 Hz, 2 H), 6.47 (s, 1 H), 4.54 - 4.62 (m, 1 H), 3.99 (s, 3 H), 3.58 (dd, J=9.9, 6.0 Hz, 1 H), 3.49 - 3.52 (m, 1 H), 3.41 (s, 3 H), 3.05 (s, 3 H), 1.33 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) ⁺ /z = 515, t _R = 3.47 min.
17		¹ H NMR (400 MHz, CDCl ₃) δ ppm 11.09 (s, 1 H), 7.88 (d, J=7.0 Hz, 2 H), 7.41 (s, 2 H), 7.04 - 7.14 (m, 4 H), 6.45 (d, J=1.8 Hz, 1 H), 4.50 - 4.65 (m, 1 H), 3.55 - 3.70 (m, 2 H), 3.46 (s, 3 H), 3.06 (s, 3 H), 1.31 (d, J=4.8 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) ⁺ /z = 446, t _R = 2.74 min.
18		¹ H NMR (500 MHz, CDCl ₃) δ ppm 8.99 (s, 1 H), 7.88 (d, J=8.8 Hz, 2 H), 7.55 (s, 1 H), 7.19 (s, 1 H), 7.12 (d, J=8.8 Hz, 2 H), 7.06 (s, 1 H), 6.43 - 6.47 (m, 1 H), 4.50 - 4.60 (m, 1 H), 3.55 - 3.59 (m, 1 H), 3.46 - 3.51 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 2.56 (s, 3 H), 1.32 (d, J=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) ⁺ /z = 477, t _R = 3.03 min.
19		¹ H NMR (500 MHz, CDCl ₃) δ ppm 9.19 (s, 1 H), 8.02 (s, 1 H), 7.88 (d, J=8.8 Hz, 2 H), 7.25 (s, 1 H), 7.13 (d, J=8.8 Hz, 2 H), 7.07 (s, 1 H), 6.43 - 6.45 (m, 1 H), 4.51 - 4.60 (m, 1 H), 3.54 - 3.60 (m, 1 H), 3.47 - 3.51 (m, 1 H), 3.40 (s, 3 H), 3.05 (s, 3 H), 2.74 (s, 3 H), 1.32 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) ⁺ /z = 477, t _R = 3.29 min.
20		¹ H NMR (500 MHz, CD ₃ OD) δ ppm 7.93 (d, J=8.8 Hz, 2 H), 7.46 (s, 1 H), 7.31 (s, 1 H), 7.18 - 7.22 (m, 3 H), 6.49 - 6.52 (m, 1 H), 4.56 - 4.63 (m, 1 H), 3.54 - 3.58 (m, 1 H), 3.49 - 3.53 (m, 1 H), 3.38 (s, 3 H), 3.11 (s, 3 H), 2.51 (s, 3 H), 1.29 (d, J=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H) ⁺ /z = 477, t _R = 3.39 min.

EXAMPLE 21

[0158]




[0159] TMSI (92 μL, 0.675 mmol) was added to a solution of Example 6 compound (60 mg, 0.135 mmol) in dry MeCN

(0.6 mL) at RT under Ar. The reaction mixture was stirred at RT overnight, then was quenched with H₂O (5 mL) and volatiles were removed *in vacuo*. The residue was diluted with EtOAc (10 mL) and 1N aqueous HCl (5 mL). After stirring for 5 min, the aqueous layer was neutralized to pH ~7-8 with solid K₂CO₃. The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with 10% (w/v) aqueous Na₂S₂O₃·5H₂O (10 mL) to remove residual iodine, washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by preparative HPLC (YMC reverse phase ODS-A-5 μm 30 x 100 mm column; flow rate = 40 mL/min, continuous gradient from 4:1 A:B to 100% solvent B over 12 min, then held for another 4 min at 100% B, where solvent A = 90:10 H₂O: MeOH and solvent B = 90:10 MeOH:H₂O) to give the title compound (31 mg, 53% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃/CD₃OD) δ ppm 7.78 (d, *J*=8.8 Hz, 2 H), 7.61 (s, 1 H), 7.51 (s, 1 H), 7.13 (s, 1 H), 7.05 (d, *J*=8.8 Hz, 2 H), 7.01 (d, *J*=2.2 Hz, 1 H), 6.33 (d, *J*=2.2 Hz, 1 H), 4.32 - 4.41 (m, 1 H), 3.59 - 3.65 (m, 1 H), 3.54 - 3.59 (m, 1 H), 3.25 (s, 3 H), 1.21 (d, *J*=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 432, *t*_R = 2.46 min.

EXAMPLE 22


[0160]



[0161] The title compound (27.5 mg; 94% yield; white solid) was prepared from Example 18 (30 mg; 0.063 mmol) using an analogous procedure to that described for the synthesis of Example 21. ¹H NMR (500 MHz, CD₃OD) δ ppm 7.93 (d, *J*=8.8 Hz, 2 H), 7.67 (s, 1 H), 7.30 (s, 1 H), 7.17 - 7.22 (m, 3 H), 6.51 (s, 1 H), 4.43 - 4.52 (m, 1 H), 3.61 - 3.70 (m, 2 H), 3.11 (s, 3 H), 2.56 (s, 3 H), 1.29 (d, *J*=6.0 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 463, *t*_R = 3.09 min.

EXAMPLE 23


[0162]




[0163] 1,3-Thiazole-2-carbonyl chloride (26 mg, 0.178 mmol) was added to a mixture of Compound 24D (30 mg, 0.089 mmol) in THF (1 mL) and saturate aqueous solution of NaHCO₃ (1 mL) at RT. The reaction mixture was vigorously stirred at RT for o/n. The reaction was diluted with EtOAc (5 mL). The layers were separated. The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (5 mL), dried (MgSO₄), and concentrated *in vacuo*. The crude residue was chromatographed (SiO₂; 12 g; continuous gradient from 100:0 hexanes: EtOAc to 0:70% hexanes:EtOAc over 25 min, held at 70% EtOAc for 15 min) to give the title compound (24.8 mg, 62% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 9.11 (s, 1 H), 7.88 - 7.94 (m, 3 H), 7.65 (d, *J*=3.3 Hz, 1 H), 7.27 (s, 1 H), 7.14 (d, *J*=8.8 Hz, 2 H), 7.05 (s, 1 H), 6.45 - 6.48 (m, 1 H), 4.48 - 4.56 (m, 1 H), 3.69 - 3.79 (m, 2 H), 3.06 (s, 3 H), 1.31 (d, *J*=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 449, *t*_R = 2.93 min.

EXAMPLE 24

[0164]




A.




[0165] A solution of 3-hydroxy-5-(4-(methylsulfonyl)phenoxy)benzoate' (3.7 g, 11.5 mmol), (R)-(-)-1-Benzyloxy-2-propanol (2.5 g, 15 mmol), polymer-supported Ph_3P (30 g of 1 mmol/g, 30 mmol) in 150 mL of THF was added dropwise a solution of DIAD (3.4 mL, 17.3 mmol) over 15 min under N_2 (internal temperature maintained at $\leq 5^\circ\text{C}$). The reaction mixture was allowed to warm to RT overnight, then filtered. The solids were thoroughly washed with THF and CH_2Cl_2 . The combined filtrates were concentrated *in vacuo*. The mixture was chromatographed on silica gel column (EtOAc/Hexane; 1:1) to give 6 g of slightly impure Part A compound (6g, 110%) as a colorless oil. $[\text{M}+\text{H}]^+=471$; ^1H NMR (400 MHz, chloroform- d) δ ppm 7.90 (2 H, d, $J=8.79$ Hz), 7.48 (1 H, s), 7.27 - 7.37 (6 H, m), 7.09 (2 H, d, $J=8.79$ Hz), 6.83 - 6.89 (1 H, m), 4.60 - 4.69 (1 H, m), 4.58 (2 H, s), 3.90 (3 H, s), 3.54 - 3.70 (2 H, m), 3.06 (3 H, s), 1.34 (3 H, d, $J=6.15$ Hz).

B.




[0166] A solution of Part A (6 g, 13 mmol), LiOH (1.6 g, 39 mmol) and H_2O (50 mL) in THF (20 mL) was stirred at RT for 3 h and then was concentrated *in vacuo*. The water solution was washed with ether (15 ml x 4), neutralized to pH=4 with concentrated HCl, extracted with EtOAc (50 mL). The organic layer was washed with H_2O , and dried (MgSO_4), filtered, and concentrated *in vacuo* to give Part B compound (5 g, 95%) as a white solid. $[\text{M}+\text{H}]^+=457$; ^1H NMR (400 MHz, chloroform- d) δ ppm 7.91 (2 H, d, $J=8.79$ Hz), 7.52 (1 H, s), 7.27 - 7.38 (6 H, m), 7.11 (2 H, d, $J=8.79$ Hz), 6.90 (1 H, t, $J=2.20$ Hz), 4.61 - 4.70 (1 H, m), 4.59 (2 H, s), 3.56 - 3.70 (2 H, m), 3.07 (3 H, s), 1.35 (3 H, d, $J=6.59$ Hz).

C.




[0167] To a RT solution of Part B Compound (630 mg, 1.38 mmol) in 1,4-dioxane (6 mL) were successively added PhCH₂OH (0.17 mL, 1.66 mmol), Et₃N (0.27 mL, 1.93 mmol) and (PhO)₂PON₃ (0.36 mL, 1.66 mmol). The reaction mixture was stirred at 120 °C overnight, then was cooled to RT. Volatiles were removed *in vacuo* and the residue was chromatographed (SiO₂; 120 g; continuous gradient from 100% hexanes to 1:1 hex:EtOAc over 40 min, then held at 1:1 hex:EtOAc for 20 min) to give Part C compound (571 mg, 74% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 562, t_R = 3.96 min.

D.



[0168] To a solution of Part C compound (570 mg, 1.02 mmol) in MeOH (30 mL) was added 10% Pd/C (57 mg, 0.536 mmol) under Ar at RT with vigorous stirring. The reaction was stirred under 1 atm of H₂ for 6 h, then was filtered through Celite®. The filtrate was concentrated *in vacuo* to give Part D Compound (312 mg, 91% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 338, t_R = 1.89 min.


E.



[0169] BOP (104 mg, 0.236 mmol) was added to a solution of 1-methyl-1H-pyrazole-3-carboxylic acid (30 mg, 0.236 mmol) in CH₂Cl₂ (0.6 mL) at RT, followed by Et₃N (0.050 mL; 0.354 mmol). After stirring at RT for 10 min, Part D compound (20 mg, 0.059 mmol) was added. The reaction was stirred at RT for 48 h, then was directly chromatographed (SiO₂; 12 g; continuous gradient from 20:80 hex:EtOAc to 100% EtOAc over 10 min, held at 100% EtOAc for 20 min) to give Part E compound (32.2 mg, 92% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.70 (s, 1 H), 7.86 (d, J=8.8 Hz, 2 H), 7.40 (d, J=2.2 Hz, 1 H), 7.35 (d, J=2.2 Hz, 1 H), 7.17 (s, 1 H), 7.07 - 7.13 (m, 3 H), 6.84 (d, J=2.2 Hz, 1 H), 6.74 (d, J=2.2 Hz, 1 H), 6.45 (s, 1 H), 4.72 - 4.81 (m, 1 H), 4.53 (dd, J=11.5, 6.6 Hz, 1 H), 4.39 (dd, J=11.5, 3.8 Hz, 1 H), 3.95 (d, J=2.7 Hz, 6 H), 3.05 (s, 3 H), 1.41 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 554, t_R = 3.03 min.

EXAMPLE 25


[0170]



[0171] KOH (8 mg, 0.135 mmol) was added to a solution of Example 24 (30 mg, 0.054 mmol) in MeOH (1 mL)/THF (1 mL)/H₂O (0.5 mL). The reaction was stirred at RT for 1 h; volatiles were removed *in vacuo* and the residue was partitioned between EtOAc (50 mL) and H₂O (5 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (5 mL), dried (MgSO₄), and concentrated *in vacuo*. The crude residue was chromatographed (SiO₂; 12 g; continuous gradient from 100:0 hex:EtOAc to 0: 100% Hex:EtOAc over 10 min, held at 100% EtOAc for 20 min) to give the title compound (7 mg, 32% yield) as a colorless sticky oil. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.68 (s, 1 H), 7.89 (d, J=8.8 Hz, 2 H), 7.40 (d, J=2.2 Hz, 1 H), 7.30 (s, 1 H), 7.13 (d, J=8.8 Hz, 2 H), 7.00 (s, 1 H), 6.84 (d, J=2.2 Hz, 1 H), 6.41 (s, 1 H), 4.47 - 4.56 (m, 1 H), 3.95 (s, 3 H), 3.68 - 3.78 (m, 2 H), 3.05 (s, 3 H), 1.30 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 446, t_R = 2.72 min.

EXAMPLE 26


[0172]



[0173] BOP (262 mg, 0.592 mmol) was added to a solution of 2-methyl-1H-imidazole-4-carboxylic acid monohydrate (85 mg, 0.592 mmol) in pyridine (1.5 mL) at RT, followed by Et₃N (0.12 mL; 0.888 mmol). After stirring at RT for 10 min, Example 24 Part D compound (50 mg, 0.148 mmol) was added. The reaction was heated at 80 °C overnight, then was cooled to RT. Volatiles were removed *in vacuo* and the residue was partitioned between EtOAc (100 mL) and H₂O (10 mL). The aqueous layer was extracted with EtOAc (2x10 mL). The combined organic extracts were washed with brine (5 mL), dried (MgSO₄), and concentrated *in vacuo*. The crude residue was purified by preparative HPLC (YMC reverse phase ODS-A-5μm 30 x 100 mm column; flow rate = 40 mL/min, continuous gradient from 4:1 A:B to 100% solvent B over 10 min, then held at 100% B for 2 min, where solvent A = 90:10:0.1 H₂O:MeOH:TFA and solvent B = 90:10:0.1 MeOH:H₂O:TFA) to give the title compound (27.5 mg, 34% yield) as a white solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 7.91 (d, J=8.8 Hz, 2 H), 7.63 (s, 1 H), 7.53 (s, 1 H), 7.26 (s, 1 H), 7.10 - 7.20 (m, 3 H), 6.50 (s, 1 H), 4.77 - 4.84 (m, 1 H), 4.40 - 4.45 (m, 1 H), 4.34 - 4.39 (m, 1 H), 3.10 (s, 3 H), 2.40 (s, 3 H), 2.34 (s, 3 H), 1.39 (d, J=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 554, t_R = 2.16 min.

EXAMPLE 27


[0174]



[0175] The title compound (7.1 mg, 44% yield, white solid) was prepared from Example 26 (20 mg; 0.036 mmol) using KOH according to the procedure described for the synthesis of Example 25. ^1H NMR (400 MHz, CD_3OD) δ ppm 7.93 (d, $J=8.8$ Hz, 2 H), 7.63 (s, 1 H), 7.17 - 7.25 (m, 3 H), 7.13 - 7.15 (m, 1 H), 6.48 (t, $J=2.2$ Hz, 1 H), 4.43 - 4.52 (m, 1 H), 3.61 - 3.70 (m, 2 H), 3.11 (s, 3 H), 2.40 (s, 3 H), 1.29 (d, $J=6.2$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 446$, $t_{\text{R}} = 2.26$ min.

EXAMPLE 28


[0176]




[0177] $\text{LiOH}\cdot\text{H}_2\text{O}$ (6 mg, 0.14 mmol) was added to a solution of Example 16 (24 mg, 0.047 mmol) in THF (0.4 mL) and H_2O (0.2 mL) at RT. The reaction was stirred at RT overnight, then was diluted with EtOAc (50 mL). The organic phase was extracted with H_2O (3 x 20 mL). The combined aqueous layers were adjusted to pH ~3 with 1N aqueous HCl and were extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO_4) and concentrated *in vacuo*. The crude product was purified by preparative HPLC (YMC reverse phase ODS-A-5 μm 30 x 100 mm column; flow rate = 40 mL/min, continuous gradient from 4:1 A:B to 100% B over 12 min, then held at 100% B for 3 min; where solvent A = 90:10:0.1 H_2O :MeOH:TFA and solvent B = 90:10:0.1 MeOH: H_2O :TFA) to afford the title compound (16.1 mg, 69% yield) as a white solid. ^1H NMR (500 MHz, CD_3OD) δ ppm 9.24 (s, 1 H), 8.52 - 8.56 (m, 1 H), 8.28 (d, $J=8.2$ Hz, 1 H), 7.94 (d, $J=8.8$ Hz, 2 H), 7.40 (s, 1 H), 7.29 (s, 1 H), 7.21 (d, $J=8.8$ Hz, 2 H), 6.52 (s, 1 H), 4.57 - 4.66 (m, 1 H), 3.55 - 3.60 (m, 1 H), 3.50 - 3.55 (m, 1 H), 3.39 (s, 3 H), 3.11 (s, 3 H), 1.31 (d, $J=6.6$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 501$, $t_{\text{R}} = 3.29$ min.

EXAMPLE 29

[0178]




A.




[0179] To a RT solution of methyl 3-hydroxy-5-(4-(methylsulfonyl)phenoxy)benzoate² (1.25 g, 3.88 mmol) in CH₂Cl₂ (20 mL) was added imidazole (581 mg, 8.54 mmol), followed by TBDPS-Cl (1.2 mL, 4.66 mmol). The reaction mixture was stirred at RT overnight, then was partitioned between EtOAc (200 mL) and H₂O (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO₄), and concentrated *in vacuo*. The residue (a beige oil) was chromatographed (SiO₂; 120 g; continuous gradient from hexane to 7:3 hex:EtOAc over 40 min, held at 7:3 hex:EtOAc for 20 min) to give Part A compound (1.98 g, 91% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 561, t_R = 4.44 min.

B.




[0180] LiOH H₂O (444 mg, 10.59 mmol) was added to a solution of Part A compound (1.98 g, 3.53 mmol) in THF (24 mL) and H₂O (12 mL) at RT. The reaction was stirred at RT overnight. The reaction was diluted with EtOAc (50 mL). The organic layer was extracted with H₂O (3 x 20 mL). The combined aqueous layers were adjusted to pH ~3 with 1N aqueous HCl and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo* to give Part B compound (1.08 g, 99%) as a white solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 7.94 (d, J=8.8 Hz, 2 H), 7.31 (s, 1 H), 7.17 (d, J=8.8 Hz, 2 H), 7.14 (s, 1 H), 6.72 (s, 1 H), 3.11 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 309, t_R = 2.25 min.

C.




[0181] To a RT solution of Part B compound (1.0 g, 3.24 mmol) in 1,4-dioxane (16 mL) were added benzyl alcohol (0.40 mL, 3.89 mmol), Et₃N (0.63 mL, 4.54 mmol) and (PhO)₂PON₃ (0.84 mL, 3.89 mmol) with stirring. The reaction mixture was stirred at 120 °C overnight, then cooled to RT. Volatiles were removed *in vacuo* and the residue was chromatographed (SiO₂; 120 g; continuous gradient from hexane to 1:1 hex:EtOAc over 40 min, then held at 1:1 hex:EtOAc for 20 min) to give Part C compound (0.65 g, 49% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃/CD₃OD) δ ppm 7.83 (d, *J*=8.8 Hz, 2 H), 7.28 - 7.38 (m, 5 H), 7.07 (d, *J*=8.8 Hz, 2 H), 6.82 (s, 1 H), 6.54 - 6.59 (m, 1 H), 6.23 (s, 1 H), 5.14 (s, 2 H), 3.02 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 414, t_R = 3.10 min.

D.



[0182] To a solution of Part C compound (150 mg, 0.36 mmol) in MeOH (10 mL) was added 10% Pd/C (15 mg) under Ar at RT with vigorous stirring. The reaction was stirred under 1 atm of H₂ for 3 h, then was filtered through Celite®. Volatiles were removed *in vacuo* to give Part D Compound (95.9 mg, 95% yield) as a beige solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 280, t_R = 1.57 min.


E.



[0183] BOP (301 mg, 0.68 mmol) was added to a solution of 4-imidazolecarboxylic acid monohydrate (76 mg, 0.68 mmol) in pyridine (3 mL) at RT, followed by Et₃N (0.19 mL; 1.36 mmol). After stirring at RT for 10 min, Part D compound (95 mg, 0.34 mmol) was added. The reaction was heated at 80 °C overnight; LC-MS showed that the starting material had disappeared. The reaction mixture was diluted with MeOH (2 mL), THF (2 mL) and H₂O (1 mL). KOH (~ 15 mg) was added to the reaction, which was stirred at RT for 1 h. Volatiles were removed *in vacuo* and the residue was partitioned between EtOAc (100 mL) and H₂O (10 mL). The pH of the aqueous layer was adjusted to ~8 with 1N aqueous HCl. The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (5 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by preparative HPLC (YMC reverse phase ODS-A-5μm 30 x 100 mm column; flow rate = 40 mL/min, continuous gradient from 4:1 A:B to 100% B over 10 min, held at 100% B for 2 min, where solvent A = 90:10 H₂O:MeOH and solvent B = 90:10 MeOH:H₂O) to give Part E


compound (34.2 mg, 27%) as a white solid ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$) δ ppm 7.86 (d, $J=8.8$ Hz, 2 H), 7.71 (s, 1 H), 7.66 (s, 1 H), 7.59 (s, 1 H), 7.15 (d, $J=8.8$ Hz, 2 H), 7.03 - 7.06 (m, 2 H), 6.30 (t, $J=2.2$ Hz, 1 H), 3.07 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/z = 374$, $t_R = 2.20$ min.

F.




[0184] Trityl chloride (29.1 mg, 0.104 mmol) was added to a solution of Part E Compound (30 mg, 0.080 mmol) in pyridine (0.2 mL) and DMF (0.4 mL) at RT. The reaction was stirred at RT overnight. Volatiles were removed *in vacuo*. The crude product was chromatographed (SiO_2 ; 4 g; continuous gradient from hexane to 1:4 hexane:EtOAc over 20 min, then held at 1:4 hexane:EtOAc for 15 min) to give Part F Compound (39 mg, 79% yield) as a white solid. ^1H NMR (500 MHz, CD_3OD) δ ppm 7.91 (d, $J=8.8$ Hz, 2 H), 7.62 (s, 1 H), 7.57 (s, 1 H), 7.38 - 7.42 (m, 9 H), 7.14 - 7.19 (m, 8 H), 7.10 (s, 1 H), 6.98 (s, 1 H), 6.27 - 6.29 (m, 1 H), 3.09 (s, 3 H); LCMS Method B (ESI, pos./neg. ion spectrum): $(\text{M}-\text{H})/z = 614$, $t_R = 3.83$ min.

G.



[0185] To a solution of Part F compound (32 mg, 0.052 mmol) in dry THF (0.5 mL) was added polymer-bound Ph_3P (45 mg, 0.135 mmol, 3 mmol/g) and (R)-methyl 2-hydroxypropanoate (7.45 μL , 0.078 mmol) under Ar at RT. DIAD (0.018 mL, 0.094 mmol) was then added dropwise at 0°C . The reaction was allowed to warm to RT and stirred for 2 h. The resin was filtered off and washed with 10 mL of THF. The combined filtrates were concentrated *in vacuo*. The crude product was chromatographed (SiO_2 ; 4 g; continuous gradient from hexane to 3:7 hex:EtOAc over 20 min, then held at 3:7 hex:EtOAc for 15 min) to give Part G compound (28.8 mg, 79% yield) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ ppm 8.95 (s, 1 H), 7.87 (d, $J=8.8$ Hz, 2 H), 7.59 (s, 1 H), 7.40 (s, 1 H), 7.32 - 7.37 (m, $J=4.9$ Hz, 9 H), 7.07 - 7.15 (m, 10 H), 6.36 (s, 1 H), 4.71 - 4.82 (m, 1 H), 3.76 (s, 3 H), 3.04 (s, 3 H), 1.60 (d, $J=6.6$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/z = 702$, $t_R = 3.96$ min.


H.




[0186] A solution of Part G Compound (26 mg, 0.037 mmol) and TFA (0.3 mL) in CH_2Cl_2 (0.6 mL) was stirred at RT for 10 min. Volatiles were evaporated *in vacuo* and the residue was chromatographed (SiO_2 ; 4 g; continuous gradient from hexane to 95:5 hex:EtOAc over 15 min, then held at 95:5 hex:EtOAc for 15 min) to give the title compound (9.5 mg, 56% yield) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ ppm 8.59 (s, 1 H), 8.19 (s, 1 H), 7.81 (d, $J=8.8$ Hz, 2 H), 7.10 (s, 1 H), 7.04 (d, $J=8.2$ Hz, 2 H), 6.92 (s, 1 H), 6.33 (s, 1 H), 4.78 (q, $J=6.6$ Hz, 1 H), 3.78 (s, 3 H), 3.03 (s, 3 H), 1.60 (d, $J=6.6$ Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 460$, $t_{\text{R}} = 2.44$ min.

EXAMPLE 30

[0187]




A.




[0188] A solution of methyl 3,5-dihydroxybenzoate (2.5 g, 14.9 mmol), 1-fluoro-4-(methylsulfonyl)benzene (5.18 g, 29.8 mmol) and anhydrous K_2CO_3 (8.23g, 59.6 mmol) in dry DMF (100 ml) was heated at 120°C for 10 h, then was cooled to RT and filtered. The solid was washed with CH_2Cl_2 (100 mL) and the combined filtrate was concentrated *in vacuo*. The residue was chromatographed (SiO_2 ; 80 g; continuous gradient from 100% hexane to 100% EtOAc over 40 min) to provide Part A compound (6.1 g) as a white solid. LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 477$, $t_{\text{R}} = 2.99$ min.

B.




[0189] A RT solution of Part A Compound (2.3 g, 4.83 mmol), and LiOH.H₂O (4.1 g, 97.5 mmol) in THF (10 mL)/H₂O (5 mL) was stirred for 2 h. The reaction was acidified to pH ~1 with 1 N aqueous HCl, extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed with brine (30 mL), dried (MgSO₄) and concentrated *in vacuo* to give Part B Compound (2.2 g) as a white solid. LCMS Method B (ESI, positive and negative ion spectra): (M-H)/z = 461, t_R = 1.43 min.

C.




[0190] To a RT solution of Part B Compound (1 g, 2.16 mmol) in 1,4-dioxane (10 mL) was added benzyl alcohol (0.27 mL, 2.59 mmol), Et₃N (0.422 mL, 3.03 mmol) and (PhO)₂PON₃ (0.562 mL, 2.59 mmol). The reaction mixture was stirred at 120 °C overnight, then was cooled to RT and concentrated *in vacuo*. The residue was chromatographed (SiO₂; 120 g; continuous gradient from 100% hexane to 40:60 hex:EtOAc over 35 min, then held at 40:60 hex:EtOAc for 25 min) to give Part C Compound (782 mg, 64% yield) as a white solid. ¹H NMR (400 MHz, DMF-d₇) δ ppm 10.13 (s, 1 H), 7.95 - 8.08 (m, 5 H), 7.26 - 7.47 (m, 10 H), 6.69 (d, J=2.2 Hz, 1 H), 3.50 (d, J=2.2 Hz, 2 H), 3.26 (d, J=2.2 Hz, 6 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 568 t_R = 3.42 min.

D.




[0191] To a RT solution of Part C Compound (780 mg, 1.374 mmol) in THF (10 mL) and MeOH (30 mL) was added 10% Pd/C (78 mg) under Ar. The reaction was stirred under 1 atm of H₂ for 1 h, then was filtered through Celite®. The filtrate was concentrated *in vacuo* to give Part D Compound (597 mg, 100% yield) as a beige solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 434, t_R = 2.54 min.


E.




[0192] EDAC (19.90 mg, 0.104 mmol) was added to a solution of sodium 5-methylthiazole-2-carboxylate (17.1 mg, 0.104 mmol) in CH_2Cl_2 (1.0 mL) and Et_3N (0.014 mL, 0.104 mmol), followed by HOBT (14 mg, 0.104 mmol) and DMAP (0.85 mg, 6.92 μmol) at RT. After stirring at RT for 10 min, Part D Compound (30 mg, 0.069 mmol) was added. The reaction mixture was stirred at RT overnight; LC-MS showed that most of the starting material had been converted to the desired product. The reaction was partitioned between EtOAc (100 mL) and H_2O (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO_4) and concentrated *in vacuo*. The crude product was chromatographed (SiO_2 ; 4 g; continuous gradient from 100% hexane to 100% EtOAc over 40 min, then held at 100% EtOAc for 10 min) to give the title compound (3.6 mg, 7% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ ppm 11.02 (s, 1 H), 7.91 - 7.96 (m, 4 H), 7.79 (s, 1 H), 7.60 (d, $J=2.2$ Hz, 2 H), 7.27 - 7.32 (m, 4 H), 6.74 (t, $J=2.2$ Hz, 1 H), 3.21 (s, 6 H), 2.53 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 559$, $t_{\text{R}} = 3.30$ min.

EXAMPLE 31**[0193]**

[0194] Compound 31 (21.6 mg; 44% yield; white solid) was prepared from Example 30 Part D Compound (40 mg; 0.092 mmol) using the same procedure as described for the synthesis of Example 29E. ^1H NMR (500 MHz, DMSO-d_6) δ ppm 10.22 (s, 1 H), 7.93 (d, $J=8.8$ Hz, 4 H), 7.80 (s, 1 H), 7.78 (s, 1 H), 7.63 (d, $J=2.2$ Hz, 2 H), 7.28 (d, $J=8.8$ Hz, 4 H), 6.64 (t, $J=2.2$ Hz, 1 H), 3.20 (s, 6 H); LCMS Method A (ESI, positive ion spectrum): $(\text{M}+\text{H})/\text{z} = 528$, $t_{\text{R}} = 2.52$ min.


EXAMPLE 32**[0195]**

A.



[0196] A solution of ethyl chlorooxoacetate (16 μ L; 0.148 mmol), Example 1 Part B Compound (40 mg, 0.114 mmol) and Et₃N (48 μ L; 0.34 mmol) in CH₂Cl₂ (1.2 mL) was stirred at RT for 2 h. The reaction mixture was chromatographed (SiO₂; 12 g; continuous gradient from 100% hex to 3:7 hex:EtOAc over 25 min, then held at 3:7 hex:EtOAc for 10 min) to give Part A Compound (40.2 mg, 78% yield) as a light yellow oil. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.83 (s, 1 H), 7.89 (d, *J*=8.8 Hz, 2 H), 7.10 - 7.14 (m, 3 H), 6.99 (s, 1 H), 6.48 (s, 1 H), 4.49 - 4.56 (m, 1 H), 4.38 - 4.43 (m, 2 H), 3.54 - 3.58 (m, 1 H), 3.46 - 3.50 (m, 1 H), 3.39 (s, 3 H), 3.05 (s, 3 H), 1.41 (t, *J*=7.1 Hz, 3 H), 1.30 (d, *J*=6.6 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 452, *t_R* = 3.04 min.


B.



[0197] Ethylamine (1.0 mL, 2.0 M in CH₃OH) was added to Example 32 Part A Compound (21.8 mg, 0.048 mmol). The reaction mixture was stirred at RT overnight. Volatiles were removed *in vacuo* and the residue was chromatographed (SiO₂; 4 g; continuous gradient from 100% hex to 1:4 hex:EtOAc over 20 min, then held at 1:4 hex:EtOAc for 10 min) to give the title compound (24.6 mg, 100%) as a light yellow oil. ¹H NMR (500 MHz, CDCl₃) δ ppm 9.23 (s, 1 H), 7.89 (d, *J*=8.8 Hz, 2 H), 7.46 (s, 1 H), 7.08 - 7.13 (m, 3 H), 7.01 (s, 1 H), 6.45 - 6.47 (m, 1 H), 4.47 - 4.55 (m, 1 H), 3.53 - 3.58 (m, 1 H), 3.46 - 3.50 (m, 1 H), 3.37 - 3.44 (m, 5 H), 3.05 (s, 3 H), 1.30 (d, *J*=6.0 Hz, 3 H), 1.23 (t, *J*=7.1 Hz, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 451, *t_R* = 3.00 min.

EXAMPLE 33

[0198]




[0199] The title compound (15 mg; 95% yield; tan solid) was prepared from Example 32 Part A Compound and NH₃ in MeOH (1 mL of a 1.0 M solution) using the same procedure as that described for the synthesis of Example 32. ¹H NMR (CDCl₃, 500 MHz) δ 9.18 (s, 1H), 7.89 (d, 2H, *J* = 8.8 Hz), 7.36 (s, 1H), 7.11 (d, 2H, *J* = 8.8 Hz), 7.09 (br. s, 1H),


7.02 (br. s, 1H), 6.47 (s, 1H), 5.79 (s, 1H), 4.56 - 4.48 (m, 1H), 3.56 (dd, 1H, J = 10.5, 6.1 Hz), 3.49 (dd, 1H, J = 10.5, 4.4 Hz), 3.39 (s, 3H), 3.05 (s, 3H), 1.31 (d, 3H, J = 6.1 Hz) ppm; LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 423, t_R = 2.70 min.

EXAMPLE 34

[0200]




A.




[0201] BBr₃ (8.62 mL of a 1.0 M solution in CH₂Cl₂; 8.62 mmol) was added to a solution of 1-bromo-3-methoxy-5-nitrobenzene (500 mg, 2.16 mmol) in CH₂Cl₂ (5 mL) at -20 °C. The reaction was allowed to warm to RT and stirred at RT overnight, then was cautiously quenched with MeOH (30 mL) and stirred for 1 h at RT. Volatiles were removed *in vacuo* to give crude Part A Compound as a brown solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 7.94 (s, 1 H), 7.62 - 7.64 (m, 1 H), 7.33 (s, 1 H), 5.84 (s, 1 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 220, t_R = 3.14 min.

B.




[0202] To a solution of Part A Compound (469 mg, 2.15 mmol) in DMF (4 mL) was added 1-fluoro-4-(methylsulfonyl)benzene (562 mg, 3.23 mmol) at RT, followed by K₂CO₃ (891 mg, 6.45 mmol). The mixture was heated at 120 °C for 48 h, then was cooled to RT. The mixture was diluted with EtOAc (50 mL), washed with H₂O (20 mL) and brine (2 x 10 mL), dried (MgSO₄) and concentrated *in vacuo*. The residual red oil was chromatographed (SiO₂; 40 g; continuous gradient from 100% hex to 2:3 hex:EtOAc over 40 min, then held at 2:3 hex:EtOAc for 10 min) to give Part B Compound (474 mg, 59% yield) as a beige solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 374, t_R = 3.23 min.

C.




[0203] To a degassed solution of Part B Compound (120 mg, 0.322 mmol) in DME (1.6 mL)/H₂O (0.4 mL) were successively added 2-fluoropyridin-4-ylboronic acid (91 mg, 0.645 mmol), K₂CO₃ (89 mg, 0.645 mmol) and (Ph₃P)₄Pd (0) (18.6 mg, 0.016 mmol). The reaction was heated at 150 °C in an Emrys Optimizer® (microwave) for 15 min, then was cooled to RT. The reaction mixture was partitioned between EtOAc (100 mL) and H₂O (10 mL). The organic phase was washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was chromatographed (SiO₂; 12 g; continuous gradient from 100% hex to 1:1 hex:EtOAc over 25 min, then held at 1:1 hex:EtOAc for 15 min) to give Part C Compound (100 mg, 80% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 389, t_R = 2.99 min.

D.




[0204] Iron dust (71.9 mg, 1.29 mmol) was added to a suspension of Part C Compound (100 mg, 0.257 mmol) in AcOH (2.5 mL). The reaction mixture was stirred at RT overnight, then was partitioned between EtOAc (100 mL) and H₂O (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with saturated aqueous NaHCO₃ (10 mL) and brine (10 mL), dried (MgSO₄) and concentrated *in vacuo* to afford Part D Compound (96.8 mg, 100%) as a beige solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 359, t_R = 2.52 min.

E.



[0205] A mixture of Part D Compound (60 mg, 0.167 mmol) and 1N aqueous NaOH (1.5 mL) was heated at 160°C in an Emrys Optimizer® (microwave) for 15 min, then was cooled to RT and partitioned between EtOAc (50 mL) and H₂O (5 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo* to afford Part E Compound (53.2 mg, 89% yield) as a white solid. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 357, t_R = 1.85 min.


F.



[0206] BOP (49.6 mg, 0.112 mmol) was added to a solution of sodium 5-methylthiazole-2-carboxylate (18.5 mg, 0.112 mmol) in pyridine (0.5 mL) at RT, followed by Et₃N (31 μL; 0.224 mmol). After stirring at RT for 10 min, Part E Compound (20 mg, 0.056 mmol) was added and the reaction was heated at 80 °C overnight, then was cooled to RT. Volatiles were removed *in vacuo* and the residue was partitioned between EtOAc (50 mL) and H₂O (5 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with sat. aq. NaHCO₃ (10 mL) and brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was chromatographed (SiO₂; 4 g; continuous gradient from 100% CH₂Cl₂ to 9:1 CH₂Cl₂:MeOH over 20 min, then held at 9:1 CH₂Cl₂:MeOH for 15 min) to give the title compound (1.2 mg, 5% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃/CD₃OD) δ ppm 7.85 (d, J=8.8 Hz, 2 H), 7.63 - 7.70 (m, 2 H), 7.53 (s, 1 H), 7.23 - 7.33 (m, 2 H), 7.10 (d, J=8.8 Hz, 2 H), 7.01 (s, 1 H), 6.68 (s, 1 H), 6.46 - 6.52 (m, 1 H), 3.02 (s, 3 H), 2.51 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 482, t_R = 3.01 min.

EXAMPLE 35


[0207]



[0208] BOP (148 mg, 0.335 mmol) was added to a solution of 1H-imidazole-4-carboxylic acid (37.5 mg, 0.335 mmol) in pyridine (1.5 mL) at RT, followed by Et₃N (93 μL; 0.67 mmol). After stirring at RT for 10 min, Example 34 Part D compound (60 mg, 0.167 mmol) was added. The reaction was heated at 80 °C for 4 h, then was cooled to RT. Volatiles were removed *in vacuo* and the residue was partitioned between EtOAc (50 mL) and H₂O (5 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with sat. aq. NaHCO₃ (10 mL) and brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was chromatographed (SiO₂; 12 g; continuous gradient from 100% CH₂Cl₂ to 95:5 CH₂Cl₂:MeOH over 30 min, then held at 95:5 of CH₂Cl₂:MeOH for 15 min) to give the title compound (72.7 mg, 96% yield) as a white solid. ¹H NMR (500 MHz, CD₃OD/CDCl₃) δ ppm 8.23 (d, J=5.5 Hz, 1 H), 7.89 - 7.94 (m, 3 H), 7.75 (s, 1 H), 7.70 (s, 1 H), 7.68 (s, 1 H), 7.55 (s, 1 H), 7.50 (d, J=5.5 Hz, 1 H), 7.20 (d, J=8.8 Hz, 2 H), 7.15 (s, 1 H), 3.09 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 453, t_R = 2.65 min.

EXAMPLE 36


[0209]




[0210] Example 35 Compound (25 mg, 0.055 mmol) was dissolved in 1N aqueous NaOH (0.3 mL) and the reaction was heated at 140°C in an Emrys Optimizer® (microwave) for 6 min, then was cooled to RT and diluted with EtOAc (50 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by preparative HPLC (YMC reverse phase ODS-A-5μm 30 x 100 mm column; flow rate = 40 mL/min, continuous gradient from 4:1 A:B to 100% B over 12 min, then held at 100% B for 3 min, where solvent A = 90:10:0.1 H₂O:MeOH:TFA and solvent B = 90:10:0.1 MeOH:H₂O:TFA) to give the title compound (6.4 mg, 26% yield) as a white solid. ¹H NMR (500 MHz, CD₃OD) δ ppm 8.77 (s, 1 H), 8.15 (s, 1 H), 7.97 (d, *J*=8.8 Hz, 2 H), 7.88 (s, 1 H), 7.71 (s, 1 H), 7.53 (d, *J*=7.1 Hz, 1 H), 7.22 - 7.28 (m, 3 H), 6.77 (s, 1 H), 6.71 (d, *J*=7.1 Hz, 1 H), 3.12 (s, 3 H); LCMS Method A (ESI, positive ion spectrum): (M+H)/*z* = 451, *t_R* = 2.14 min.

EXAMPLE 37

[0211]




A.



[0212] A solution of 3-nitro-5-(trifluoromethyl)phenol (207 mg, 1.0 mmol), 1-fluoro-4-(methylsulfonyl)benzene (523 mg, 3.0 mmol) and anhydrous K₂CO₃ (414 mg, 3.0 mmol) in dry DMF (100 ml) was heated at 120°C for 3 h. The reaction was cooled to RT, filtered and washed with CH₂Cl₂ (100 mL). The filtrate was concentrated *in vacuo*. The crude material


was chromatographed (SiO₂; 40 g; EtOAc/hexane) to provide Part A Compound (361 mg, 100% yield) as a white solid. ¹H NMR (CDCl₃, 500 MHz) δ 8.06 - 7.96 (m, 2 H), 7.28 - 7.22 (m, 5 H), 3.06 (s, 3H) ppm; LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 362, t_R = 3.24 min.

B.



[0213] A solution of Part A Compound (361 mg, 1.0 mmol) and Pd/C (10%, 50 mg) in MeOH (3 mL) was stirred under an atmosphere of H₂ for 1 h. The reaction was diluted with CH₂Cl₂ (10 mL) and filtered through Celite®. The filtrate was concentrated to afford crude Part B Compound as a tan solid (331 mg, 100% yield). This material was used in the next step without further purification. LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 332, t_R = 2.99 min.

C.



[0214] Part C compound (41 mg, 95% yield, white solid) was prepared by the reaction of Part B compound (33.1 mg; 0.1 mmol) and thiazole-2-carbonyl chloride (19 mg, 0.13 mmol) according to the procedure described for the synthesis of Example 1. ¹H NMR (CDCl₃, 500 MHz) δ 9.29 (s, 1 H), 8.00 - 7.91 (m, 3H), 7.82 (s, 1 H), 7.73 (s, 1 H), 7.69 (d, 1 H, J = 2.8 Hz), 7.16 (d, 2H, J = 8.2 Hz), 7.12 (s, 1 H), 3.08 (s, 3H); HPLC Method B; t_R = 6.83 min; LCMS Method A (ESI, positive ion spectrum): (M+H)/z = 433, t_R = 3.47 min.

References

[0215]

1. The required (S)-3-(1-methoxypropan-2-yloxy)-5-(4-(methylsulfonyl)phenoxy)benzoic acid was prepared according to known procedures in WO 2005/121110 and WO 2005/080359.
2. The required methyl 3-hydroxy-5-(4-(methylsulfonyl)phenoxy)benzoate was prepared according to known procedures in WO 2005/121110.

ASSAYS AND BIOLOGICAL DATA

[0216] Compounds of formula I of the invention, including compounds described in the Examples hereof, have been tested in the following assay and have shown to be activators of glucokinase. In general, compounds of the present invention, such as particular compounds disclosed in the following examples, have been identified to enhance the activity of glucokinase at concentrations equivalent to, or more potently than, 100 μM, preferably 10 μM, more preferably 1 μM, thereby demonstrating compounds of the present invention as especially effective enhancers of activity of glucokinase. Potencies can be calculated and expressed as either EC₅₀ (concentration to achieve 50% of full activation) and/or the

maximum percentage activation above background, and refer to activity measured employing the assay system described below.

[0217] Compounds of formula I of the invention, including compounds described in the Examples hereof, have been tested in the following assay and have shown to be activators of glucokinase.

Glucokinase Tandem Enzymatic Assay

[0218] Enzymatic activity of human glucokinase (GK) was measured by incubating GK, ATP, and glucose for discrete time periods followed by quenching with EDTA (ethylenediamine tetra-acetic acid). Relative amounts of product glucose-6-phosphate (G6P) were measured by then running a detection assay using G6P dehydrogenase and measuring the conversion of ThioNAD (thio-nicotinamide adenine dinucleotide) to ThioNADH (thio-dihydronicotinamide adenine dinucleotide) at a wavelength of 405 nm. This 'uncoupled' enzymatic reaction is denoted as the GK 'tandem' assay. Activation of GK by compounds can be assessed using this assay. The GK tandem assay protocol described below was followed using a range of activator compound concentrations from 0 to 100 μ M at 5 and 12 mM of glucose. Human full-length glucokinase (GK, 15 nM) was incubated with 5 or 12 mM glucose in a 384 well black microtiter plate with a clear bottom. To initiate the GK reaction, magnesium-ATP (3 mM final concentration) was added to GK in buffer (final buffer conditions of 25 mM HEPES buffer, pH 7.1, containing 1 mM dithiothreitol and 5% DMSO). The total reaction volume was 20 μ L. The reaction was allowed to proceed for ten minutes and was then quenched with 5 μ L EDTA; 45 mM final). The components of the detection reaction, ThioNAD and G6PDH (glucose-6-phosphate dehydrogenase) (final concentrations of 650 μ M and 3.33 Units, respectively), were then added together in a volume of 25 μ L, (to give a total volume of 50 μ L). Absorbance measurements were made at 405 nm on a Spectramax Plus 384 absorbance plate reader (Molecular Devices). Absorbance was read, background glucose-6-phosphate levels were subtracted, after which activation was calculated as a percentage of control activity. Control activity was determined using GK in the presence of vehicle (DMSO), with background glucose-6-phosphate subtracted. Background glucose-6-phosphate was determined by pre-quenching GK with EDTA prior to reaction initiation with ATP.

Expression and Purification of Human GK

[0219] Full-length human hepatic GK (untagged) was expressed in BL21 STAR (DE3)pLysS cells (Invitrogen) at 25 °C as described by Mookhtiar et al. (1). The protein was purified essentially as described by Lange (2) with a slight modification. Briefly, cell pellets were lysed via three rounds of freezing and thawing, centrifuged at 15000g for clarification, and precipitated with 40-65% $(\text{NH}_4)_2\text{SO}_4$. The resulting pellet was resuspended in buffer, dialyzed, and applied directly to a Q-Sepharose (Sigma) column followed by elution with a linear 100-600 mM KCl gradient. GK containing fractions were pooled, dialyzed overnight vs. 25 mM Hepes pH 7.2/1 mM MgCl_2 /1 mM EDTA/0.1 M KCl/1 mM DTT, then dialyzed again with same buffer with 10% glycerol added.

References

[0220]

1. Mookhtiar, K.A. et al., "Heterologous expression and characterization of rat liver glucokinase regulatory protein", *Diabetes*, 45:1670-1677 (1996).
2. Lange, A.J. et al., "Expression and site-directed mutagenesis of hepatic glucokinase", *Biochem. J.*, 277:159-163 (1991).

[0221] Biological data for select Examples are shown in the table below.

Example No.	EC ₅₀ (nM) with Human Glucokinase @ 12 mM Glucose
18	67
22	77
5	165
6	191
8	513
31	575

For other Examples, the EC₅₀ values could not be calculated from the activation curves, so the maximal activation data (expressed as a % of basal activation) for some select Examples are shown in the table below.


Example No.	Maximal activation (%) Human Glucokinase @ 12 mM Glucose
7	131%
37	163%

In Vivo Studies: Oral Glucose Tolerance Test (OGTT)

[0222] Oral glucose tolerance tests were carried out on male DIO (diet-induced obese) C57BL/6J mice fed a high fat diet (60% kcal from fat) for 26 weeks prior to experimentation. Mice were fasted overnight before use for experiments. A test compound or vehicle (10% dimethyl acetamide + 10% ethanol + 10% Cremophore + 70% water) was given orally 60 min before oral administration of a glucose solution at a dose of 2 g/kg body weight (oral glucose tolerance test; OGTT). Blood glucose levels were measured from tail-bled samples taken at different time points before and after administration of glucose (time course of 2 hours). A time curve of the blood glucose was generated and the change from baseline area-under-the curve (ΔAUC) from 0-120 min was calculated (the time glucose administration being time zero). Example 6 reduced glucose AUC levels in an OGTT test in DIO mice as described above by 66% at a 30 mg/kg dose.

Claims

1. A compound having the structure



or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof;

where Q is R¹ optionally substituted with one or two additional substituents independently chosen from R⁴ and R⁵ that may be the same or different;

R¹ is a monocyclic or bicyclic heteroaryl ring, containing a nitrogen atom adjacent to the carbonyl linked ring carbon and possessing one additional nitrogen atom, and when substituents are attached to a N atom of the ring, a quaternary nitrogen center is not formed;

R⁴ and R⁵ are the same or different and are independently selected from alkyl, arylalkyl, alkoxy carbonyl, or carboxyl; R⁶ is H;

R⁷ and R⁸ (regardless of which group each is a part of) are the same or different and are independently selected from H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R⁷ and R⁸ are cyclized together to form a 3- to 7-membered heterocycle;

R⁹ (regardless of which group it is a part of) is independently selected from H, alkyl, aryl, or arylalkyl;

R¹⁰ (regardless of which group it is a part of) is independently selected from alkyl, aryl, heteroaryl, aralkyl, or heteroarylalkyl;

R² is Y-Z-;


Z is O or a bond;

Y is C₁₋₆alkyl-, aryl-, heterocyclyl-, or heteroaryl-; -

wherein each Y is independently optionally substituted by up to 3 R¹² groups;

each R¹² is independently selected from F, Cl, Br, I, -CH₃, -F, -CN, -NO₂, -NH₂, C₁₋₆alkyl, OC₁₋₆alkyl, -COOH, OH, aryloxy, heteroaryloxy, heterocyclyloxy, -S-R¹⁰, -S(O)-R¹⁰, -SO₂R⁹, -SO₂NR⁷R⁸, -NR⁷R⁸, -CO₂R⁹, -C(O)N⁷R⁸, N-linked amide (-NR⁷C(O)R⁸), N-linked sulfonamide (-NR⁹SO₂R¹⁰), N-linked carbamate (-NR⁸CO₂R¹⁰), O-linked carbamate (-OCONR⁷R⁸), N-linked urea (-NR⁹C(O)NR⁷R⁸), -(CH₂)_p-PO(OR⁷)(OR⁸), -(CH₂)_p-PO(OR⁷)R⁸, -(CH₂)_p-O-PO(OR⁷)R⁸, -(CH₂)_p-O-PO-(R⁷)R⁸, -(CH₂)_p-P(O)(R⁷)R⁸, aryl, heteroaryl, or heterocyclyl;

R³ is




each a is an integer independently selected from 1, 2, 3; and

p is an integer independently selected from 0, 1 or 2

wherein "cycloalkyl" includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings.


2. The compound as defined in Claim 1 wherein the R¹ ring is a nitrogen containing a 5- or 6-membered monocyclic heteroaryl ring or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.

3. The compound as defined in Claim 1 wherein Q is




or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.

4. The compound as defined in Claim 1 wherein the R² group is




or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.

5. The compound as defined in Claim 1 wherein Q is




and
R² is




or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.












6. The compound as defined in Claim 1 wherein the compound is






or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.


7. A compound having the structure







or



or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof.


8. A pharmaceutical composition comprising a compound as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof, including enantiomers and diastereomers thereof, and a pharmaceutically acceptable carrier thereof.

9. A pharmaceutical composition as defined in Claim 8, further comprising another therapeutic agent which is an anti-diabetic agent, anti-hyperglycemic agent, anti-hyperinsulinemic agent, anti-retinopathic agent, anti-neuropathic agent, anti-nephropathic agent, anti-atherosclerotic agent, anti-infective agent, anti-ischemic agent, anti-hypertensive agent, anti-obesity agent, anti-dyslipidemic agent, anti-hyperlipidemic agent, anti-hypertriglyceridemic agent, anti-hypercholesterolemic agent, anti-ischemic agent, anti-cancer agent, anti-cytotoxic agent, anti-restenotic agent, anti-pancreatic agent, lipid lowering agent, appetite suppressant, memory enhancing agent, or cognitive agent.

10. A compound as defined in any one of claims 1 to 7 for use in a method for treating, preventing, or slowing the progression of a disease requiring glucokinase activator therapy.
11. The compound as defined in Claim 10 wherein the disease is diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy, and glaucoma.
12. A compound as defined in any one of claims 1 to 7 for use in a method of activating the enzyme glucokinase.
13. A compound as defined in any one of claims 1 to 7 for use in a method of treating Type II diabetes.

Patentansprüche

1. Verbindung mit der Struktur



oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon;

wo Q R¹ ist, gegebenenfalls substituiert mit einem oder zwei zusätzlichen Substituenten, unabhängig ausgewählt aus R⁴ und R⁵, die gleich oder verschieden sein können;

R¹ ein monocyclischer oder bicyclischer Heteroarylring ist, enthaltend ein Stickstoffatom, angrenzend an den Carbonyl-verknüpften Ringkohlenstoff, und besitzend ein zusätzliches Stickstoffatom, und wenn Substituenten an ein N-Atom des Rings angefügt sind, kein quaternäres Stickstoffzentrum gebildet wird;

R⁴ und R⁵ gleich oder verschieden sind und unabhängig aus Alkyl, Arylalkyl, Alkoxy-carbonyl oder Carboxyl ausgewählt sind;

R⁶ H ist;

R⁷ und R⁸ (ungeachtet dessen, von welcher Gruppe jedes ein Teil ist) gleich oder verschieden sind und unabhängig aus H, Alkyl, Cycloalkyl, Aryl, Arylalkyl, Heteroaryl und Heteroarylalkyl ausgewählt sind oder R⁷ und R⁸ miteinander cyclisiert sind, um einen 3- bis 7-gliedrigen Heterocyclus zu bilden;

R⁹ (ungeachtet dessen, von welcher Gruppe es ein Teil ist) unabhängig aus H, Alkyl, Aryl oder Arylalkyl ausgewählt ist;

R¹⁰ (ungeachtet dessen, von welcher Gruppe es ein Teil ist) unabhängig aus Alkyl, Aryl, Heteroaryl, Arylalkyl oder Heteroarylalkyl ausgewählt ist;

R² Y-Z- ist;


Z O oder eine Bindung ist;

Y C₁-₆Alkyl-, Aryl-, Heterocyclyl- oder Heteroaryl- ist;

wobei jedes Y unabhängig gegebenenfalls mit bis zu 3 R¹²-Gruppen substituiert ist;

jedes R¹² unabhängig aus F, Cl, Br, I, -CH₃-aFₐ, CN, NO₂, NH₂, C₁-₆Alkyl, OC₁-₆Alkyl, -COOH, OH, Aryloxy, Heteroaryloxy, Heterocyclioxy, -S-R¹⁰, -S(O)-R¹⁰, -SO₂R⁹, -SO₂NR⁷R⁸, -NR⁷R⁸, -CO₂R⁹, -C(O)N⁷R⁸, N-verknüpftem Amid (-NR⁷C(O)R⁸), N-verknüpftem Sulfonamid (-NR⁹SO₂R¹⁰), N-verknüpftem Carbamat (-NR⁸CO₂R¹⁰), O-verknüpftem Carbamat (-OCONR⁷R⁸), N-verknüpftem Harnstoff (-NR⁹C(O)NR⁷R⁸), - (CH₂)ₚ-PO(OR⁷)(OR⁸), -(CH₂)ₚ-PO(OR⁷)R⁸, -(CH₂)ₚ-O-PO(OR⁷)R⁸, -(CH₂)ₚ-O-PO-(R⁷)R⁸, -(CH₂)ₚ-P(O)R⁷R⁸, Aryl, Heteroaryl oder Heterocyclyl ausgewählt ist;

R³



ist;


jedes a eine ganze Zahl, unabhängig ausgewählt aus 1, 2, 3, ist; und

p eine ganze Zahl, unabhängig ausgewählt aus 0, 1 oder 2, ist,

wobei "Cycloalkyl" gesättigte oder teilweise ungesättigte (enthaltend 1 oder 2 Doppelbindungen) cyclische Kohlenwasserstoffgruppen, enthaltend 1 bis 3 Ringe, einschließt.


2. Verbindung, wie definiert in Anspruch 1, wobei der R¹-Ring ein Stickstoff enthaltender 5- oder 6-gliedriger monocyclischer Heteroarylring ist, oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.

3. Verbindung, wie definiert in Anspruch 1, wobei Q



ist, oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.


4. Verbindung, wie definiert in Anspruch 1, wobei die R²-Gruppe




und CF₃ ist,

oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.

5. Verbindung, wie definiert in Anspruch 1, wobei Q




ist; und

R²

ist;


10 oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.

6. Verbindung, wie definiert in Anspruch 1, wobei die Verbindung




25 ist, oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.


7. Verbindung mit der Struktur



5




10




15

20




25

30




35

40




45


50



55



oder




oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon.

8. Pharmazeutische Zusammensetzung, umfassend eine Verbindung, wie definiert in einem der Ansprüche 1 bis 7, oder ein pharmazeutisch verträgliches Salz davon und alle Stereoisomere davon, einschließlich Enantiomeren und Diastereomeren davon, und einen pharmazeutisch verträglicher Träger davon.
9. Pharmazeutische Zusammensetzung, wie definiert in Anspruch 8, weiterhin umfassend ein anderes therapeutisches Mittel, welches ein antidiabetisches Mittel, antihyperglykämisches Mittel, antihyperinsulinämisches Mittel, antiretinopathisches Mittel, antineuropathisches Mittel, antineuropathisches Mittel, antiatherosklerotisches Mittel, antiinfektiöses Mittel, antiischämisches Mittel, antihypertensives Mittel, Mittel gegen Fettsucht, antidiyslipidämisches Mittel, antihyperlipidämisches Mittel, antihypertriglyceridämisches Mittel, antihypercholesterinämisches Mittel, antiischämisches Mittel, Antikrebsmittel, antizytotoxisches Mittel, antirestenotisches Mittel, antipankreatisches Mittel, lipidsenkendes Mittel, Appetitzügler, das Gedächtnis verbesserndes Mittel oder kognitives Mittel ist.
10. Verbindung, wie definiert in einem der Ansprüche 1 bis 7, zur Verwendung in einem Verfahren zum Behandeln, Verhindern oder Verlangsamen des Fortschritts einer Krankheit, die Glucokinase-Aktivator-Therapie erfordert.
11. Verbindung, wie definiert in Anspruch 10, wobei die Krankheit Diabetes, Hyperglykämie, beeinträchtigte Glucosetoleranz, Insulinresistenz, Hyperinsulinämie, Retinopathie, Neuropathie, Nephropathie, verzögerte Wundheilung, Atherosklerose und ihre Folgeerscheinungen, anormale Herzfunktion, myokardiale Ischämie, Schlaganfall, Metabolisches Syndrom, Bluthochdruck, Fettleibigkeit, Dyslipidämie, Hyperlipidämie, Hypertriglyceridämie, Hypercholesterinämie, niedriger HDL, hoher HDL, nicht-kardiale Ischämie, Infektion, Krebs, vaskuläre Restenose, Pankreatitis, neurodegenerative Krankheit, Lipidstörungen, kognitive Beeinträchtigung und Demenz, Knochenkrankheit, HIV-Protease-assoziierte Lipodystrophie und Glaukom ist.
12. Verbindung, wie definiert in einem der Ansprüche 1 bis 7, zur Verwendung in einem Verfahren zum Aktivieren des Enzyms Glucokinase.
13. Verbindung, wie definiert in einem der Ansprüche 1 bis 7, zur Verwendung in einem Verfahren zum Behandeln von Typ-II-Diabetes.

Revendications

1. Composé présentant la structure:



ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci;

dans lequel Q est R¹ éventuellement substitué avec un ou deux substituants supplémentaires indépendamment choisis parmi R⁴ et R⁵ qui peuvent être identiques ou différents;

R¹ est un cycle hétéroaryle monocyclique ou bicyclique, contenant un atome d'azote adjacent au carbone de cycle lié au carbonyle et possédant un atome d'azote supplémentaire et, lorsque les substituants sont attachés à un atome N du cycle, un centre d'azote quaternaire n'est pas formé;

R⁴ et R⁵ sont identiques ou différents et sont indépendamment choisis parmi un alkyle, un arylalkyle, un alcoxy-carbonyle ou un carboxyle;

R⁶ est H;

R⁷ et R⁸ (sans se soucier de quel groupe chacun fait partie) sont identiques ou différents et sont indépendamment choisis parmi H, un alkyle, un cycloalkyle, un aryle, un arylalkyle, un hétéroaryle et un hétéroarylalkyle, ou R⁷ et R⁸ sont cyclisés ensemble pour former un hétérocycle de 3 à 7 membres;

R⁹ (sans se soucier de quel groupe il fait partie) est indépendamment choisi parmi H, un alkyle, un aryle ou un arylalkyle;

R¹⁰ (sans se soucier de quel groupe il fait partie) est indépendamment choisi parmi un alkyle, un aryle, un hétéroaryle, un aralkyle ou un hétéroarylalkyle;

R² est Y-Z-;


Z est O ou une liaison;

Y est un alkyle C₁-₆-, un aryl-, un hétérocyclyl- ou un hétéroaryl-;

où chaque Y est indépendamment éventuellement substitué par jusqu'à 3 groupes R¹²;

chaque R¹² est indépendamment choisi parmi F, Cl, Br, I, -CH₃, -F, -CN, -NO₂, -NH₂, un alkyle C₁-₆-, un Oalkyle C₁-₆-, -COOH, OH, un aryloxy, un hétéroaryloxy, un hétérocycloxy, -S-R¹⁰, -S(O)-R¹⁰, -SO₂R⁹, -SO₂NR⁷R⁸, -NR⁷R⁸, -CO₂R⁹, C(O)NR⁷R⁸ un amide lié à N (-NR⁷C(O)R⁸), un sulfonamide lié à N (-NR⁹SO₂R¹⁰), un carbamate lié à N (-NR⁹CO₂R¹⁰), un carbamate lié à O (-OCONR⁷R⁸), une urée liée à N (-NR⁹C(O)NR⁷R⁸), -(CH₂)ₚ-PO(OR⁷)(OR⁸), -(CH₂)ₚ-PO(OR⁷)R⁸, -(CH₂)ₚ-O-PO(OR⁷)R⁸, -(CH₂)ₚ-O-PO-(R⁷)R⁸, -(CH₂)ₚ-P(O)R⁷R⁸, un aryle, un hétéroaryle ou un hétérocycle;

R³ est:




chaque a est un nombre entier indépendamment choisi parmi 1, 2, 3; et


p est un nombre entier indépendamment choisi parmi 0, 1 ou 2;

dans lequel un « cycloalkyle » inclut des groupes hydrocarbures cycliques partiellement insaturés (contenant 1 ou 2 liaisons doubles) contenant de 1 à 3 cycles.

2. Composé selon la revendication 1, dans lequel le cycle R¹ est un cycle hétéroaryle monocyclique de 5 ou 6 membres contenant de l'azote, ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.



3. Composé selon la revendication 1, dans lequel Q est:






ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.

4. Composé selon la revendication 1, dans lequel le groupe R^2 est:




ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.

5. Composé selon la revendication 1, dans lequel:
Q est:




et
 R^2 est:



ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.


6. Composé selon la revendication 1, où le composé est:



ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.


7. Composé présentant la structure:

5




10

15




20

25




30

35




40





45




50



55



OU



ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci.

8. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 7, ou un sel pharmaceutiquement acceptable de celui-ci, et tous les stéréoisomères de celui-ci, incluant des énantiomères et des diastéréoisomères de celui-ci, et un support pharmaceutiquement acceptable de celui-ci.

9. Composition pharmaceutique selon la revendication 8, comprenant en outre un autre agent thérapeutique qui est un agent anti-diabétique, un agent anti-hyperglycémique, un agent anti-hyperinsulinémique, un agent anti-rétino-

pathique, un agent anti-neuropathique, un agent anti-néphropathique, un agent anti-athérosclérotique, un agent anti-infectieux, un agent anti-ischémique, un agent anti-hypertensif, un agent anti-obésité, un agent anti-dyslipidémique, un agent anti-hyperlipidémique, un agent anti-hypertriglycéridémique, un agent anti-hypercholestérolémique, un agent anti-ischémique, un agent anti-cancer, un agent anti-cytotoxique, un agent anti-resténotique, un agent anti-pancréatique, un agent abaissant les lipides, un coupe-faim, un agent augmentant la mémoire ou un agent cognitif.

10. Composé selon l'une quelconque des revendications 1 à 7 pour une utilisation dans une méthode de traitement, de prévention ou de ralentissement de la progression d'une maladie nécessitant une thérapie par activateur de glucokinase.

11. Composé selon la revendication 10, dans lequel la maladie est un diabète, une hyperglycémie, une diminution de la tolérance au glucose, une résistance à l'insuline, une hyperinsulinémie, une rétinopathie, une neuropathie, une néphropathie, une cicatrisation de blessure retardée, une athérosclérose et ses suites, une fonction cardiaque anormale, une ischémie myocardique, une attaque, un syndrome métabolique, une hypertension, une obésité, une dyslipidémie, une hyperlipidémie, une hypertriglycéridémie, une hypercholestérolémie, un bas niveau de HDL, un haut niveau de LDL, une ischémie non cardiaque, une infection, un cancer, une resténose vasculaire, une pancréatite, une maladie neurodégénérative, des troubles lipidiques, une déficience cognitive et une démence, une maladie des os, une lipodystrophie associée à une protéase de VIH et un glaucome.

12. Composé selon l'une quelconque des revendications 1 à 7 pour une utilisation dans une méthode d'activation de l'enzyme glucokinase.

13. Composé selon l'une quelconque des revendications 1 à 7 pour une utilisation dans une méthode de traitement d'un diabète de type II.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2007061923 A [0003]
- US 5594016 A [0101]
- WO 0121602 A [0102]
- US 6414002 B [0102]
- WO 0059506 A [0103]
- WO 0127128 A [0104]
- WO 9938501 A [0105]
- WO 9946272 A [0105]
- WO 9967279 A [0105]
- WO 9967278 A [0105]
- WO 9961431 A [0105]
- WO 9926659 A [0106]
- US 5614492 A, Habener [0108]
- WO 9943663 A [0110]
- US 5595872 A [0113]
- US 5739135 A [0113]
- US 5712279 A [0113]
- US 5760246 A [0113]
- US 5827875 A [0113]
- US 5885983 A [0113]
- US 5962440 A [0113]
- US 3983140 A [0114]
- US 4231938 A [0114]
- US 4346227 A [0114]
- US 4448784 A [0114]
- US 4450171 A [0114]
- US 5354772 A [0114]
- US 5006530 A [0114]
- US 5177080 A [0114]
- US 4681893 A [0114]
- US 5273995 A [0114]
- US 5385929 A [0114]
- US 5686104 A [0114]
- US 5011930 A [0114]
- US 5260440 A [0114]
- US 5753675 A [0114]
- US 4613610 A [0114]
- WO 8603488 A [0114]
- US 4647576 A [0114]
- WO 8607054 A [0114]
- FR 2596393 [0114]
- EP 0221025 A [0114]
- US 4686237 A [0114]
- US 4499289 A [0114]
- EP 0142146 A2 [0114]
- US 5506219 A [0114]
- US 5691322 A [0114]
- GB 2205837 A [0116]
- US 5712396 A [0117]
- US 4871721 A [0117]
- US 4924024 A [0117]
- US 3674836 A [0119]
- US 4759923 A [0119]
- US 4027009 A [0119]
- WO 9712615 A [0124]
- WO 9712613 A [0124]
- WO 9638144 A [0124]
- US 5612359 A [0125]
- US 6043265 A [0125]
- WO 0001389 A [0125]
- US 5541204 A [0128]
- US 5770615 A [0128]
- US 5491134 A [0128]
- US 5776983 A [0128]
- US 5488064 A [0128]
- WO 9721993 U [0131]
- WO 9900353 A [0131]
- WO 00039077 A [0131]
- EP 1177791 A [0134]
- WO 2005121110 A [0215]
- WO 2005080359 A [0215]

Non-patent literature cited in the description

- LIAG, Y. et al. *Biochem. J.*, 1995, vol. 309, 167-173 [0003]
- MATSCHINSKY, F.M. et al. *Diabetes*, 2006, vol. 55, 1 [0004]
- Glucokinase and Glycemic Disease. Basics to Novel Therapeutics. 2004, 360-378 [0004]
- Glucokinase and Glycemic Disease. Basics to Novel Therapeutics. Karger, 2004, 360-378 [0004] [0005]
- FYFE, M.C. et al. *Diabetologia*, 2007, vol. 50, 1277 [0004] [0005]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1985, 1418 [0068]
- CAMILLE G. WERMUTH et al. *The Practice of Medicinal Chemistry*. Academic Press, 1996 [0073]
- Design of Prodrugs. Elsevier, 1985 [0073]
- A Textbook of Drug Design and Development. Harwood Academic Publishers, 1991, 113-191 [0073]

- **BERNARD TESTA ; JOACHIM M. MAYER.** Hydrolysis in Drug and Prodrug Metabolism. Wiley-VCH, 2003 [0073]
- **GREENE, T.W. et al.** Protecting Groups in Organic Synthesis. Wiley, 1999 [0084] [0094]
- **SUAIFAN et al.** *Tetrahedron*, 2006, vol. 62, 11245-11266 [0085]
- **LI et al.** *Org. Lett.*, 1999, vol. 1, 91 [0085]
- **FORD et al.** *J. Am. Med. Assoc.*, 2002, vol. 287, 356-359 [0097]
- **ARBEENY et al.** *Curr. Med. Chem. - Imm., Endoc. & Metab. Agents*, 2001, vol. 1, 1-24 [0097]
- **MURAKAMI et al.** A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor α (PPAR α) and PPAR γ ; Effect of PPAR α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats. *Diabetes*, 1998, vol. 47, 1841-1847 [0102]
- **HUGHES et al.** *Biochemistry*, 1999, vol. 38 (36), 11597-11603 [0105]
- **YAMADA et al.** *Bioorg. & Med. Chem. Lett.*, 1998, vol. 8, 1537-1540 [0105]
- **ASHWORTH et al.** *Bioorg. & Med. Chem. Lett.*, 1996, vol. 6 (22), 1163-1166 2745-2748 [0105]
- **BILLER et al.** *J. Med. Chem.*, 1988, vol. 31 (10), 1869-1871 [0117]
- **BILLER, S.A. et al.** *Current Pharmaceutical Design*, 1996, vol. 2, 1-40 [0117]
- **ORTIZ DE MONTELLANO, P. et al.** *J. Med. Chem.*, 1977, vol. 20, 243-249 [0118]
- **COREY et al.** *J. Am. Chem. Soc.*, 1976, vol. 98, 1291-1293 [0118]
- **MCCLARD, R.W. et al.** *J. Am. Chem. Soc.*, 1987, vol. 109, 5544 [0118]
- **CAPSON, T.L.** *Ph.D., dissertation*, June 1987, 16, 17, 40-43 48-51 [0118]
- *Drugs of the Future*, 1999, vol. 24, 9-15 [0120]
- **NICOLOSI et al.** The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. *Atherosclerosis*, 1998, vol. 137 (1), 77-85 [0120]
- **GHISELLI, G.** The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB 100-containing lipoprotein. *Cardiovasc. Drug Rev.*, 1998, vol. 16 (1), 16-30 [0120]
- **SMITH, C. et al.** RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor. *Bioorg. Med. Chem. Lett.*, 1996, vol. 6 (1), 47-50 [0120]
- ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals. **KRAUSE, B.R. et al.** *Inflammation: Mediators and Pathways*. CRC Press, Inc., publ, 1995, 173-198 [0120]
- **SLISKOVIC et al.** ACAT inhibitors: potential anti-atherosclerotic agents. *Curr. Med. Chem.*, 1994, vol. 1 (3), 204-225 [0120]
- **STOUT et al.** Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. *Chemtracts: Org. Chem.*, 1995, vol. 8 (6), 359-362 [0120]
- *Atherosclerosis*, 1995, vol. 115, 45-63 [0122]
- *J. Med. Chem.*, 1998, vol. 41, 973 [0122]
- *Drugs of the Future*, 1999, vol. 24, 425-430 [0123]
- **SENDOBRY et al.** Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. *Brit. J. Pharmacology*, 1997, vol. 120, 1199-1206 [0124]
- **CORNICELLI et al.** 15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease. *Current Pharmaceutical Design*, 1999, vol. 5, 11-20 [0124]
- **HERTZOG, D.L.** *Expert Opin. Ther. Patents*, 2004, vol. 14, 1435-1452 [0127]
- **MOOKHTIAR, K.A. et al.** Heterologous expression and characterization of rat liver glucokinase regulatory protein. *Diabetes*, 1996, vol. 45, 1670-1677 [0220]
- **LANGE, A.J. et al.** Expression and site-directed mutagenesis of hepatic glucokinase. *Biochem. J.*, 1991, vol. 277, 159-163 [0220]